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Abstract: Background: Elevated lipoprotein(a) [Lp(a)] is a genetic risk 
factor for cardiovascular disease (CVD) in general population studies, 
but its contribution to CVD risk in patients with established CVD or on 
statin therapy is uncertain.  
Methods: Patient-level data from seven randomized placebo-controlled 
statin outcomes trials were collated and harmonized to calculate hazard 
ratios for CVD, defined as fatal or non-fatal coronary heart disease, 
stroke, or revascularisation procedures. Hazard ratios for CVD were 
estimated within each trial across pre-defined Lp(a) groups (15-<30, 30-
<50, and ≥50 vs. <15 mg/dL), before pooling estimates using multivariate 
random-effects meta-analysis.  
Findings: Analyses included data for 29069 patients with repeat Lp(a) 
measurements (mean age 62 years; 28% female; 5751 events during 95576 
person-years at risk). Initiation of statin therapy reduced low-density-
lipoprotein cholesterol (mean change [95% CI]:  -39% [-43, -35]) without 
a significant change in Lp(a). Associations of baseline and on-statin 
treatment Lp(a) with CVD risk were approximately linear with increased 
risk at Lp(a) values ≥30 mg/dL for baseline Lp(a) and ≥50 mg/dL for on-
statin Lp(a). Age- and sex-adjusted hazard ratios across Lp(a) groups 
[referent: Lp(a) <15 mg/dL] were 1·04 (0·91, 1·18), 1·11 (1·00, 1·22), 
and 1·31 (1·08, 1·58) for baseline Lp(a), and 0·94 (0·81, 1·10), 1·06 
(0·94, 1·21), and 1·43 (1·15, 1·76) for on-statin Lp(a). Hazard ratios 
were virtually identical after further adjustment for prior CVD, 
diabetes, smoking, systolic blood pressure, low-density-lipoprotein 
cholesterol, and high-density-lipoprotein cholesterol. The association of 
on-statin Lp(a) with CVD risk was stronger than for on-placebo Lp(a) 
(interaction P=0·010) and was more pronounced at younger ages 
(interaction P=0·008) without effect modification by any other patient-
level or study-level characteristics.  
Interpretation: In this individual-patient meta-analysis of statin-
treated patients, elevated baseline and on-statin Lp(a) showed an 
independent, approximately linear relationship with CVD risk. This study 
provides a rationale for testing the Lp(a) lowering hypothesis in CVD 
outcomes trials.  
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Responses to comments of editors and reviewers 
 
Note: Lines numbers listed in this document are for the version of the manuscript with track changes. 
Editors' comments 
 
Comment #1: 
In responses to reviewers' points, provide text changes together with line numbers.  
 
Response: As requested, we provide the text changes together with line numbers 
 
Comment #2: 
When interpreting editorial points made by reviewers, please remember we will further edit the final 
manuscript if accepted.  
 
Response: Thank you for pointing this out to us.  
 
Comment #3: 
Please indicate any authors who are full professors.  
 
Response: In the revised list of affiliations of the manuscript (lines 8-28), it is now specified 
who of the co-authors are full professors. 
 
Comment #4: 
For randomised trials please follow the CONSORT reporting guidelines  http://www.consort-
statement.org and include a CONSORT checklist.  
 
Response: Our study was a meta-analysis evaluating the association of Lp(a) with disease risk of 
clinical trial data and not a primary report of a clinical trial reporting on the effect of an 
intervention on disease risk. We therefore believe this point does not apply to our study; 
nevertheless, in Supplementary Table 2, we provide a flow chart designed per CONSORT 
recommendations showing – for each trial – the numbers of people who were assessed for 
eligibility, were randomised, had missing Lp(a), were included in the analysis, and developed the 
CVD outcome during follow-up. 
 
Comment #5: 
Please follow CONSORT for abstracts (eg method of randomisation).  
 
Response: Please see reply to editorial comment #4. 
 
Comment #6: 
At the end of the methods section please state the role of the funder in: data collection, analysis, 
interpretation, writing of the manuscript and the decision to submit. Please also state which author(s) 
had access to all the data, and which author(s) were responsible for the decision to submit the 
manuscript etc.  
 
Response: We report this information on lines 166-169 of the revised manuscript. 
 
Comment #7: 
Please give 95% confidence intervals for hazard ratios/odds ratios.  
 
Response: Done.  
*Reply to Reviewers Comments
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Comment #8: 
Limit summary to pre-defined primary endpoints and safety endpoints.  
 
Response: Done.  
 
Comment #9: 
Report all outcomes specified in the protocol.  
 
Response: We confirm that we report on all outcomes pre-specified in the statistical analysis 
plan for this project (developed prior to any combined analyses being undertaken, but after 
results of some trials were known).  
 
Comment #10: 
Please explain any deviations from the protocol.  
 
Response: There were no deviation from the pre-specified statistical analysis plan of this project. 
 
Comment #11: 
Clearly denote analyses of exploratory outcomes as post-hoc.  
 
Response: Done. 
 
Comment #12: 
P values should be exact to 4 decimal places (eg p<0.0001). Two decimals are acceptable in tables for 
non-significant p-values.  
 
Response: Done. 
 
Comment #13: 
Please provide absolute numbers to accompany all percentages.  
 
Response: We have revised the text in lines 172-175 accordingly. 
 
Comment #14: 
Please provide numbers at risk for Kaplan-Meier plots.  
 
Response: As requested, the Kaplan-Meier plot in this document (Response Figure 1) is 
provided together with numbers at risk. The main manuscript does not contain Kaplan-Meier 
plots. 
 
Comment #15: 
Please provide the text, tables and figures in an editable format.  
 
Response: Done. 
 
Comment #16: 
Ensure that figures conform with the Lancet artwork guidelines.  
 
Response: Done. 
 
Comment #17: 
Include a maximum of six main figures or tables, moving others to the web appendix.  
 
Response: Done. 
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Comment #18: 
Provide a research in context panel.  
 
Response: The research context panel has been updated to include a systematic review of prior 
evidence done. 
 
Comment #19: 
Provide signed authorship statements and conflict of interest forms and summarise authors' 
disclosures in the manuscript.  
 
Response: Done. 
 
Comment #20: 
Provide statements for any personal communication and for any named person in the 
acknowledgements saying that they agree to be acknowledged.  
 
Response: Done.  
 
Comment #21: 
Add a statement of author contributions at the end of the text.  
 
Response: Already done. 
 
Comment #22: 
Please ensure that there is a section in the Methods section confirming ethics approval and consent 
from all patients has been obtained.  
 
Response: We now state in the methods section on line 110 that: “All contributing trials have 
obtained ethics approval and patients’ informed consent.” 
 
Comment #23: 
Confirm that all authors have seen and approved of the final text.  
 
Response: The corresponding authors Peter Willeit and Sam Tsimikas confirm that all authors 
have seen and approved the final text.  
 
Comment #24: 
Avoid endnotes.  
 
Response: Done. 
 
Comment #25: 
Please note our guideline length for research articles is 3000 words. Allowing for additional material 
requested by reviewers and editors we can allow a little leeway but we hope for final manuscript 
below 3500 words (4500 words for RCTs).  
 
Response: Done. 
 
Comment #26: 
Provide a revised manuscript, a tracked changes version showing the changes made, and a point-by-
point response to ALL EDITORS' and reviewers' comments - typed immediately following each 
specific point.  
 
Response: Done. 
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Comment #27: 
Avoid boxes for replies.  
 
Response: Done. 
Reviewer #1 
This analysis addresses an important question regarding Lp(a) risk in patients treated with statins. 
Thus, these data differ from the Lp(a) Collaboration Study. The use of patient specific data, statistical 
methods and analysis are a strength. The authors use these data to present a case for the Novartis 
antisense therapy for Lp(a). Overall, the data is important, but the commercial link is overdone in the 
view of this Reviewer. 
 
Comment #1: 
In the introduction, revise the statement on the limitation of single statin RCT analyses.  
 
Response: We have now clarified on lines 86-93 of the revised manuscript that “a major 
limitation of all post hoc studies reporting Lp(a) levels and outcomes is that they involved only a 
small number of patients with Lp(a) values above 50 mg/dL and therefore were uniformly 
underpowered to test the hypothesis that elevated Lp(a) levels are associated with increased CVD 
risk in the setting of statin therapy or prior history of CVD.” 
 
 
Comment #2: 
Discussion. Page 8. Paragraph 2. Lines 2-3. A small angiographic study. Provide reference. If the 
authors are using FATS or HATS as a reference, how do they account for the reduction in Lp(a) in the 
niacin arm as a confounder?  
 
Response: We used the post-hoc analysis of FATS as a reference (Maher et al JAMA 1995, now 
cited). The study combined three treatment arms (i.e. lovastatin 40 mg daily plus colestipol 30 g 
daily, niacin 4 g daily plus colestipol, and placebo) and compared LDL-C non-responders (+6%, 
n=36) with responders (-40%, n=84). The baseline and on-treatment Lp(a) levels were not 
significantly different between LDL-C responders and non-responders (37 vs. 35 mg/dL at 
baseline; 34 vs. 29 mg/dL on-treatment). Therefore, this appears to address potential 
confounding. However, our point is that the paper’s conclusion may be faulty due to low power, 
low baseline Lp(a), and type-2 error. It is contradicted by our much larger study. This paper has 
been cited very frequently and has made it into treatment paradigms of the practicing physician 
that, if LDL-C is controlled, Lp(a) is not a risk factor. This had likely led to many physicians not 
measuring or even thinking about Lp(a) as a risk factor. The potential adverse impact to patients 
of this underpowered post-hoc analysis cannot be quantitated but is likely significant.  
 
In further proof, both FOURIER and ODYSSEY OUTCOMES have now presented (but not 
published yet) their data and both show elevated baseline Lp(a) remains a risk factor even with 
exceedingly low LDL-C <50 mg/dL. 
 
We have added the following statement to the revised discussion (lines 309-314): “In support of 
our observation in this study, the trials FOURIER (European Atherosclerosis Society, May 2018) 
and ODYSSEY OUTCOMES (International Atherosclerosis Society, June 2018) have recently 
presented preliminary findings of their data, both showing that elevated baseline Lp(a) remains a 
risk factor even with on-treatment LDL-C <50 mg/dL in patients treated with statins and PCSK9 
inhibitors.” Moreover, data presented from ODYSSEY OUTCOMES indicate that lowering of 
Lp(a) with alirocumab is associated with reduced major adverse cardiac outcomes, independent 
of the effects of alirocumab on LDL-C. 
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Comment #3: 
Omit the speculative comment on association shapes and clinical benefit at different levels of Lp(a) 
concentration.  
 
Response: We have now omitted this comment on lines 319-321 of the revised manuscript. 
 
Reviewer #2 
Lipoprotein(a) (Lp(a)) is one of the last bastions in lipid management and new potent therapies for 
lowering Lp(a) will be a major focus of future clinical trials. Nine of ten WHO criteria to justify 
screening for Lp(a) are met and reduction of ASCVD risk with intervention is the missing link that 
could revolutionize lipid management in high risk patients and their families in the next decade. Most 
of the observational evidence supporting Lp(a) as a risk factor for ASCVD (and aortic stenosis to 
lesser extent) comes from primary prevention cohorts. The present analysis from the Lp(a) Studies 
Collaboration shows that in patients derived from several large statin trials Lp(a) remains an 
independent risk factor for incident events. This finding is crucially important, because of antecedent 
uncertainties in part related to faulty or biased analyses. The results of this powerful analysis will pave 
the way for future intervention trials with ASO and siRNa directed at apo(a).  
 
Comment #1: 
The selection process for the 29,069 patients from the seven statin trials might have biased the results. 
What re-assurance can you provide for lack of bias from the study design adopted?  
 
Response:  As noted by the reviewer, the seven statin trials we analysed involved 29,069 patients 
with Lp(a) measurements and 15,975 patients without Lp(a) measurements. In none of these 
trials were patients selected on the basis of Lp(a) levels. The choice for selecting patients for 
Lp(a) assessment in the current analysis was entirely based on the availability of sufficient blood 
sample at baseline and/or follow-up. The analysis shown in revised Supplementary Table 1 
confirms that there were minimal differences in baseline characteristics of patients with or 
without Lp(a) measurements. This is now also stated in the methods section, lines 116-118.  
 
Comment #2: 
Clarify why results differ from those of the previous study by O'Donoghue et al in JACC.  
 
Response: Associations in the three trials reported by O'Donoghue et al (PROVE-IT, CARE, and 
PEACE) were somewhat weaker than our analysis (see summary in Response Table 1 below). 
Three features crucially distinguish our analysis from the O'Donoghue paper. First, the three 
trials in the paper by O'Donoghue et al recorded a low number of incident events (i.e. 191 in 
PROVE-IT, 15 in CARE, and 343 in PEACE vs. 5751 in our analysis), leading to limited 
statistical power and wide 95% confidence intervals of estimated hazard ratios. Second, in 
contrast to our analysis which defined Lp(a) categories informed by ESC/EAS guideline 
recommendations (Eur Heart J 2016;37:2999–3058) (i.e. <15, 15-<30, 30-<50, and ≥50 mg/dL), 
O'Donoghue et al defined Lp(a) categories in each trial differently (i.e. trial-specific quintiles). 
Third, the boundaries of these Lp(a) categories were lower than the ones used in our analysis (see 
Response Table 1) and hence a threshold effect at high Lp(a) concentrations might have been 
missed. It has to be noted that the O'Donoghue paper also includes a meta-analysis of eight 
additional trials, but neither of these additional trials evaluated a statin intervention.  
We have now added the following statement to the discussion (lines 272-276) to address this 
important point: “In contrast to a previous analysis of individual-patient data by O’Donoghue et 
al, our study afforded higher statistical power because it involved >10 times more CVD events, 
and hence was able to characterise associations with high Lp(a) concentrations more precisely. 
Moreover, the present analysis used clinically-relevant Lp(a) categories informed by guideline 
recommendations, as opposed to trial-specific quintiles.” 
 
Response Table 1. Comparison of results from the paper by O'Donoghue et al to our analysis. 
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Trial No. of patients / events Comparison groups Hazard ratio (95% CI) 
PROVE-IT 2529 / 191 <1.8 vs. >31.3 mg/dL 1.00 (0.63-1.59) 
CARE 785 / 15 <3 vs. ≥41 mg/dL 1.08 (0.69-1.68) 
PEACE 3394 / 343 <4.6 vs. >49 mg/dL 1.07 (0.75-1.53) 
Our analysis 29069 / 5751 <15 vs. ≥50 mg/dL 1.35 (1.11-1.66) 
 
Comment #3: 
Index event bias can plague the assessment of a risk factor for recurrent events. This can be an issue 
in secondary prevention trials. Was this a problem and how was it addressed?  
 
Response: We expect that effects of index event bias are limited in our present analysis because: 
(i) we observed similarly strong associations between Lp(a) and CVD risk in people with and 
without baseline CVD; (ii) we observed concordant correlations between Lp(a) and other CVD 
risk factors in people with and without baseline CVD, whereas index event bias typically 
characterised by such correlations being directionally discordant (Response Table 2); and (iii) 
we employed multivariable adjustment, which can partial control index event bias (discussed in 
JAMA 2011; 305(8): 822–823) Still, because we cannot entirely rule out presence of index event 
bias, we now state in the limitation section of the discussion on lines 338-340 that: “we cannot 
rule out that index event bias may have attenuated effect sizes in secondary prevention trials, 
although the scope of this bias was reduced by employment of multivariable adjustment.” 
 
Response Table 2. Correlates of Lp(a) at baseline in patients with and without pre-existing 
CVD. 
Clinical variables 
% difference in Lp(a) (95% CI) per SD higher value of clinical variables 
or compared to reference group of clinical variables 
Patients without CVD  
at baseline (n=13817) 
Patients with CVD  
at baseline (n=15252) 
Age 1% (-2 to 4) -1% (-3 to 1) 
Sex, females vs. males 14% (-4 to 36) 8% (2 to 15) 
Diabetes, yes vs. no -41% (-60 to -11) -15% (-22 to -8) 
Smoking, yes vs. no 5% (-0 to 11) -2% (-7 to 4) 
SBP -1% (-6 to 4) -3% (-6 to -1) 
LDL-Ccorr  -17% (-27 to -6) -16% (-27 to -3) 
HDL-C 9% (4 to 14) 6% (0 to 11) 
BMI -4% (-6 to -2) -8% (-11 to -4) 
For categorical clinical variables, % differences shown are for females compared to males, patients with 
diabetes compared to those without, and patients who were smokers compared to those who were not.  
 
Comment #4:  
Lp(a) is notoriously difficult to assay accurately. Isoform independent assays are essentially non-
existent, despite apparent claims to the contrary. What assays were employed in the various studies 
and how were the mass values standardised? How long were samples stored for and under what 
conditions; was this uniform across studies?  
 
Response: The assays used are noted below in Response Table 3. All studies with two 
exceptions used commercially available assays used in routine clinical care, which disposed of 
acceptable metrics of accuracy and precision. MIRACL used a UCSD validated in-house ELISA, 
and 4D applied an in-house ELISA with a combination of poly- and monoclonal antibodies used 
in many dozens of studies before. As shown in Response Table 3 below, duration of storage of 
blood samples before Lp(a) measurement was variable within and between trials, ranging from 
immediate processing to storage for up to 18 years. We did note this previously as a limitation 
and have now further expanded this point to take your comments into consideration (discussion 
section, lines 332-334).   
 
Response Table 3. Assays used to measure Lp(a). 
Trial Assay manufacturer (assay type) Sample Storage Storage 
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type time temperature 
AFCAPS NR NR NR NR 
CARDS Technoclone (Immunoturbidimetric assay) Serum 5-9 yrs -70°C 
4D In-house (ELISA) Serum 10 yrs -70°C 
JUPITER Randox (Immunoturbidimetric assay) Plasma 6-10 yrs -70°C 
LIPID Abbott Diagnostics (Latex particle immunoassay) Plasma 17-18 yrs -70°C 
MIRACL In-house (ELISA) Plasma 5 yrs -70°C 
4S Pharmacia (Radioimmunoassay) Serum 0-1.8 yrs -70°C 
NR=not reported. 
 
Comment #5: 
The studies included in this analysis were heterogeneous: primary and secondary stable coronary 
prevention; diabetics; CKD on hemodialysis; an ACS group. The MIRACL study was a short trial and 
measurement of Lp(a) in an ACS setting may be unreliable. Was this accounted for in the statistical 
analyses?  
 
Response: It is correct that we investigated the association of baseline and on-statin Lp(a) with 
CVD risk in a broad range of types of patient populations, enhancing the generalisability of our 
findings and their clinical translation. To account for the differences in population types in our 
analysis, we estimated (and provide in Supplementary Table 5) hazard ratios within each study 
separately, before calculating a pooled estimate using random-effects meta-analysis (which in 
contrast to fixed-effects models relaxes the strong assumption that the studies estimate the same 
true effect and rather estimates a distribution of effects). Besides a more pronounced association 
at younger ages, subsidiary meta-regression analyses showed similar magnitudes of associations 
according to prior CVD, diabetes, or length of follow-up (for detailed results, please see 
Supplementary Figure 2), thereby leaving some of the between-study heterogeneity 
unexplained. In the revised discussion on lines 340-342, we therefore acknowledge that “our 
analysis identified moderate to high between-study heterogeneity, which could not be explained 
by baseline disease status (i.e. prior CVD or prior diabetes) nor by differing lengths of follow-up 
periods”. Finally, in MIRACL, acute phase response effects on Lp(a) are unlikely to be 
significant because Lp(a) levels in the placebo group remained unchanged between the baseline 
to the 16-week assessment. In specific, the mean % change of Lp(a) in this timeframe was -0.7% 
(95% confidence interval: -3.2 to +1.9%; P=0.600). 
 
Comment #6: 
Assay heterogeneity can be addressed by genotyping apo(a) for CNV in K-IV2 or for the 2 Clarke 
SNPs. Do the authors have data on apo(a) gene variants in this cohort to corroborate their assertions 
or at least to check for the validity of their Lp(a) mass assay(s) and the back calculation of mass from 
apparent molar values, as was suggested in the methods.  
 
Response: LPA SNPs were not measured in these studies nor is DNA available to do so now. 
KIV2 repeats were measured in 4D, but this study only contributed 1249/29,069 patients. KIV-2 
repeats also can only explain 25-50% of Lp(a) levels, so this is not likely to be an appropriate 
method to test assay heterogeneity.  
 
Comment #7: 
Did the authors examine heterogeneity of effect sizes by country of origin of participants in the trials? 
For example, in Europe a negative gradient in plasma Lp(a) levels has been described from north to 
south; were the results different in 4S from other trials?  
 
Response: This is an important point, but these data are not available for all the studies in the 
meta-analysis to perform this analysis.  
 
Comment #8: 
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The relationship between Lp(a) and ASCVD may vary by gender; how was this adjusted for given 
wide differences in proportion of women in the trials; should the inferences from the analyses be 
guarded in women?  
 
Response: Our data indicates that the associations between high Lp(a) and CVD risk are not 
modified by sex. As shown in Figure 3, the hazard ratio for CVD with Lp(a) ≥50 mg/dL was 
1.39 (1.19, 1.63) in men vs. 1.40 (1.12, 1.75) in females for baseline Lp(a) and 1.56 (1.26, 1.94) 
in men vs. 1.51 (1.19, 1.91) in females for on-statin Lp(a). P values for interaction were 0.91 for 
baseline Lp(a) and 0.79 for on-statin Lp(a). 
 
Comment #9: 
Lp(a) levels are often inversely related to plasma triglycerides (TGs), because theoretically apo(a) can 
transfer after secretion into plasma to TRL, especially in the postprandial status; while HDL-C is 
described and adjusted for, TG levels are not accounted for; can these data be provided?  
 
Response: We obtained triglyceride data from the trials CARDS, 4D, JUPITER, LIPID, 
MIRACL, and 4S. In analyses further adjusted for triglyceride levels, hazard ratios were virtually 
identical. These results have been added to Supplementary Table 2 and are commented on in 
the results section (line 210-213). 
Reviewer #3 
Comment #1: 
The authors excluded 35.5% of the data because these patients had missing Lp(a) measurements. Did 
these patients with missing data systematically differ from patients with Lp(a) data?  
 
Response: Revised Supplementary Table 1 demonstrated that there were little differences in 
baseline characteristics of patients with or without Lp(a) measurements (also now commented on 
in the methods section, lines 116-118). The same point has been raised reviewer #2 (comment 
#1), where a more detailed response can be found. 
 
Comment #2: 
The authors reported imputing using a study-specific mixed model, can the authors detail this model? 
Was missing data mean-imputed based on this model?  
 
Response: For each trial separately, we fitted a linear mixed-effects model, as  
 
                                       
 
where     is the j-th log-transformed Lp(a) measurements for patient i,    is the assigned 
treatment group (1 if statin and 0 if placebo), and     is the time from baseline of the j-th Lp(a) 
measurement.   ,   , and    are fixed effects, whereas     is the random intercept allowed to 
vary at the patient level and     is the random error term. For patients who had Lp(a) available 
only at one of the two time points (i.e. either at baseline or at follow-up), Lp(a) at the other time 
point was mean-imputed based on the expected Lp(a) change estimated from assigned treatment 
and duration of the trial. To help clarify the model specification, we have rephrased the methods 
section (lines 122-128) accordingly.  
 
Comment #3: 
How did the authors test the proportional hazards assumption? Did they test this assumption per-trial 
or over all trials?  
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Response: We tested the proportional assumption using on Schoenfeld residuals in models fitted 
separately to each study, before combining estimates in a meta-analysis. Detailed results of this 
analysis are provided in Response Table 4. We have expanded our statement on this in the 
revised manuscript on line 145-146: “The assumption for the proportionality of hazards was 
tested using Schoenfeld residuals and was met”. 
 
Response Table 4. Results from testing the PH assumption using Schoenfeld residuals. 
Trial Baseline Lp(a) 
χ2 (d.f.) 
Baseline Lp(a) 
P value 
On-statin Lp(a) 
χ2 (d.f.) 
On-statin Lp(a) 
P value 
AFCAPS 2.15 (3) 0.543 0.23 (3) 0.973 
CARDS 3.48 (3) 0.324 0.55 (3) 0.907 
4D 1.06 (3) 0.786 2.36 (3) 0.501 
JUPITER 2.74 (3) 0.433 3.02 (3) 0.388 
LIPID 1.54 (3) 0.674 4.83 (3) 0.185 
MIRACL 5.51 (3) 0.138 3.13 (3) 0.372 
4S 4.97 (3) 0.174 3.45 (3) 0.328 
Overall 21.44 (21) 0.432 17.57 (21) 0.676 
d.f.=degrees of freedom. 
 
Comment #4: 
In the results the authors report incidences per 1,000 person years. I'm not certain readers could easily 
digest how 55.3/1000 person years relates to risk.  
 
Response: We agree with the reviewer that the interpretation of cumulative incidences over a 
specified time period (for example, cumulative 1-year CVD risk) would be more intuitive for 
readers than the interpretation of incidence rates. Nevertheless, because this project involved 
time-to-event data with different durations of follow-up contributed by each patient, we 
identified CVD incidence rate as the appropriate measure of disease incidence. In analogy to this, 
we chose to report hazard ratios rather than risk ratios as a measure of relative risk. If the 
reviewer or editorial team has a strong view on this, the results section containing the incidence 
rates (lines 194-198) could be omitted.  
 
Comment #5: 
How did CVD hazard rates differ by trial? May I ask to see Kaplan-Meier curves of CVD per trial? 
Even random-effects CpH models cannot overcome disparate baseline hazard rates between trials.  
 
Response: Incidence rates varied substantially across trials, as expected given their different 
inclusion criteria (listed in Table 1 of the manuscript). The incidence rates for CVD per 1,000 
person-years (in descending order) are: 832.42 in MIRACL, 105.5 in 4D, 84.48 in LIPID, 68.65 
in 4S, 17.97 in CARDS, 12.29 in AFCAPS, and 11.21 in JUPITER. A Kaplan-Meier plot with 
numbers-at-risk is provided in Response Figure 1. Because of these expected differences, we 
pre-specified in our analysis plan the use of a two-stage approach (rather than a single random-
effects Cox model), whereby separate Cox models are fitted for each trial first, before study-
specific effect estimates are pooled using random-effects meta-analysis.  
 
Response Figure 1. Kaplan-Meier plots for incident CVD for each trial. 
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Comment #6: 
Why did the authors choose to discretize Lp(a) rather than analyze as a continuous variable?  
 
Response: We decided a priori to use Lp(a) categories in our analysis because we regard this as 
clinically more relevant. In particular, we aimed to provide clarity concerning any threshold 
effects for CVD risk. While the 2016 ESC/EAS Guidelines for the Management of 
Dyslipidaemias considers CVD risk to be significant in people with Lp(a) values above 50 
mg/dL (European Heart Journal 2016;37,2999–3058), many clinical laboratories and 
practitioners designate Lp(a) levels already above 30 mg/dL as being elevated (Arterioscler 
Thromb Vasc Biol 2015;35:996–1001). Furthermore, our focus on these guideline-informed 
categorisations of Lp(a) is also relevant to upcoming clinical trials because people with Lp(a) 
≥50 mg/dL are considered a potential target subpopulation for therapeutic intervention 
specifically aimed at lowering Lp(a). 
 
 
Comment #7: 
The authors note this analysis is well-powered but do not present any formal power analysis.  
 
Response: We have conducted a series of simulation studies to evaluate the statistical power in 
this random-effects meta-analysis. Response Figure 2 plots statistical power as a function of the 
total number of participants to detect a hazard ratio of 1.4 or greater, assuming a similar 
distribution of patients across Lp(a) categories as in our dataset, a cumulative CVD incidence in 
the reference group similar as in our dataset (17.2%), and moderate-to-high between-study 
heterogeneity (τ2 = 0.4). By conducting a total of 1000 repetitions, the simulation evaluated 
statistical power in an modelled meta-analysis involving between 1000 and 40000 participants. 
Point estimates for statistical power are presented together with binomial confidence intervals. 
Details of the methods involved in this simulation are available in a separate methods paper 
(Journal of Statistical Software 2016;74(12)1-25; DOI: 10.18637/jss.v074.i12).  
 
Response Figure 2. Statistical power according to total number of participants in a modelled 
meta-analysis (for modelling parameters, please see text above). 
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Reviewer #4 
The investigators have conducted a meta-analysis using patient-level data from seven randomized 
placebo-controlled statin outcomes trials to evaluate CVD risk in patients on statin therapy.  The 
investigators concluded that patients with elevated Lp(a) on statin therapy, primarily with levels of 
>50 mg/dL, are at a significantly higher risk of CVD. The hazard ratios for high Lp(a) at baseline and 
under statin therapy were of similar magnitude, reflecting that statin therapy may not appreciably 
affect Lp(a)-mediated risk in patients with elevated Lp(a). Overall, the methodology of the study 
conducted is robust.  
 
My main concern is that I do not find the results to be surprising. There is prior evidence that the 
effect of statin therapy on Lp(a) levels is minimal. The LDL receptor does not seem to have a major 
role in lipoprotein(a) clearance; hence statins are generally ineffective in the reduction of 
lipoprotein(a) concentration. In the absence of such evidence, it is hard for me to even justify the 
premise of the study and it is hard to think of a valid reason why the investigators have gone through 
this effort of conducting an IPD meta-analysis. There is no other finding in this study which is novel. 
All of the findings described in the paper have been published previously by larger IPD meta-
analyses.  
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Response: Although we agree with you on the issue of the statin therapy affecting Lp(a) levels 
and the role of the LDLR, the general thinking among clinicians has been that once one is on 
statin therapy, the need to measure Lp(a) or to consider it a risk factor is no longer relevant. 
Furthermore, several underpowered trials and observational studies have suggested as such (for 
instance, O'Donoghue et al, discussed in detail in our response to comment #2 of reviewer #2), 
while others suggested residual risk when Lp(a) is elevated. Thus, pending a randomized trial, 
this meta-analysis which specifically addressed the statin question and which has not been 
studied previously in secondary prevention cohorts is ideal to address this question. This is the 
first, adequately powered analysis to formally assess the effect of baseline and on-statin 
treatment effect that resolves this controversy with the best possible data pending an outcomes 
trial.   
Technical points 
Comment #1: 
When you submit the revised paper, please provide: (i) one "clean" copy of your manuscript; (ii) one 
copy where your changes are highlighted (tracked changes); (iii) A separate, point by point response 
to the editorial and referee comments typed immediately following each specific point above. (iv) 
Any images and/or tables (even if no revisions have been made).  
 
Response: Done. 
 
Comment #2: 
Please do NOT include a copy of your original manuscript.  All text files should be supplied as MS 
Word files.  
 
Response: Done. 
 
Comment #3: 
Please also supply the word count for the body of your paper and your abstract (word count for the 
body of your paper should not include abstract, references, figures or tables).  
 
Response: Done. 
 
Comment #4: 
To enable readers to better appreciate research findings and to encourage full and transparent 
reporting of outcomes, The Lancet family journals offer to publish a webaddress in accepted paper 
that links to the study's protocol on the author's institutional website (see Lancet 2009; 373: 992). This 
is particularly encouraged for randomised controlled trials, but is welcome for all types of research.  
 
Response: The Lipoprotein(a) Studies Collaboration is described at the webpage 
https://clinicalepi.i-med.ac.at/research/lpasc/.  
 
Comment #5: 
We ask all authors of, and all contributors (including medical writers and editors) to specify their 
conflicts of interest (if any) and individual contributions to a manuscript under consideration at The 
Lancet. The Lancet will not publish any articles unless we have a completed author statement form, 
conflict of interest form, and the signatures of all authors. Please sign and complete the author 
statement form (http://www.thelancet.com/for-authors/forms#author-sigs) and the ICMJE conflicts of 
interest statement form (http://www.thelancet.com/for-authors/forms#icmje-coi), and either upload 
the signed copies in to EES with your manuscript, scan and email to editorial@lancet.com. In 
addition, please also include written consent of any cited individual(s) noted in acknowledgments or 
personal communications.  
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The Lancet's requirements are described in more detail at the Information for Authors page at: 
http://www.thelancet.com/authors/lancet/authorinfo 
 
The editors may use such information as a basis for editorial decisions and will publish such 
disclosures if they are believed to be important to readers in judging the manuscript. In summary, the 
signed statements we require are authors' contribution and signatures, signed conflict of interest 
statement for ALL authors, signed copyright permissions for previously published material, signed 
consent from individuals cited in the Acknowledgements, signed consent for use of cited personal 
communications, and signed patient's consent and permission to publish (if not already submitted).  
 
Response: Done.  
 
 - 1 - 
 
Baseline and on-statin treatment lipoprotein(a) levels predict cardiovascular events: 1 
An individual-patient-data meta-analysis of statin outcome trials 2 
Brief title: Lp(a) and CVD risk in statin outcome trials 3 
Peter Willeit, Paul M. Ridker, Paul J. Nestel,
 
John Simes, Andrew M. Tonkin, Terje R. 4 
Pedersen, Gregory G. Schwartz, Anders G. Olsson, Helen M. Colhoun, Florian Kronenberg, 5 
Christiane Drechsler, Christoph Wanner, Samia Mora, Anastasia Lesogor, Sotirios Tsimikas 6 
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria, and 7 
Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK (P 8 
Willeit MD PhD); Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 9 
USA (Prof P M Ridker MD, Samia Mora, MD); Baker Heart & Diabetes Institute, 10 
Melbourne, Australia (Prof P J Nestel MD); NHMRC Clinical Trials Centre, University of 11 
Sydney, Australia (Prof J Simes MD); Department of Epidemiology and Preventive 12 
Medicine, Monash University, Melbourne, Australia (Prof A M Tonkin
 
MD); Oslo University 13 
Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway (Prof T R Pederson 14 
MD); Division of Cardiology, VA Medical Center and University of Colorado School of 15 
Medicine, Denver, CO, USA (Prof G G Schwartz MD PhD); Department of Medicine and 16 
Care, Faculty of Health Sciences, University of Linköping, Linköping, Sweden (Prof A G 17 
Olsson MD PhD); MRC Human Genetics Unit, Centre for Genomic and Experimental 18 
Medicine, MRC Institute of Genetics & Molecular Medicine, Edinburgh, UK (Prof H 19 
Colhoun MD);
 
Division of Genetic Epidemiology, Department of Medical Genetics, 20 
Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria 21 
(Prof F Kronenberg MD),  ivision o   ephrolog ,  epartment o   nternal  edi ine   and 22 
 omprehensive Heart  ail re  entre,  niversit  Hospital o  W r   rg, W r   rg, Germany 23 
(C Drechsler MD PhD, Prof C Wanner MD); Novartis Pharma AG, Basel, Switzerland (A 24 
Lesogor MD); Vascular Medicine Program, Sulpizio Cardiovascular Center, Division of 25 
Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA 26 
(Prof S Tsimikas MD) 27 
Key words: Lipoprotein(a), cardiovascular disease, statin, outcomes, meta-analysis 28 
3458 words, 3 tables, 3 figures, 5 supplementary tables, 2 supplementary figures 29 
Correspondence to: Associate Professor Peter Willeit MD PhD, Department of Neurology, 30 
Medical University of Innsbruck, Innsbruck, Austria, phone: +43 512 504-83493; email: 31 
peter.willeit@i‑med.ac.at; or Professor Sotirios  Tsimikas MD, Vascular Medicine Program, 32 
Sulpizio Cardiovascular Center, University of California San Diego,  phone: +1 8585346109; 33 
email: stsimikas@ucsd.edu.  34 
Manuscript
 - 2 - 
 
Abstract (300 words) 35 
Background: Elevated lipoprotein(a) [Lp(a)] is a genetic risk factor for cardiovascular 36 
disease (CVD) in general population studies, but its contribution to CVD risk in patients with 37 
established CVD or on statin therapy is uncertain.  38 
Methods: Patient-level data from seven randomized placebo-controlled statin outcomes trials 39 
were collated and harmonized to calculate hazard ratios for CVD, defined as fatal or non-fatal 40 
coronary heart disease, stroke, or revascularisation procedures. Hazard ratios for CVD were 41 
estimated within each trial across pre-defined Lp(a) groups (15-<30, 30-<50, and ≥50 vs. <15 42 
mg/dL), before pooling estimates using multivariate random-effects meta-analysis.  43 
Findings: Analyses included data for 29069 patients with repeat Lp(a) measurements (mean 44 
age 62 years; 28% female; 5751 events during 95576 person-years at risk). Initiation of statin 45 
therapy reduced low-density-lipoprotein cholesterol (mean change [95% CI]:  -39% [-43, -46 
35]) without a significant change in Lp(a). Associations of baseline and on-statin treatment 47 
Lp(a) with CVD risk were approximately linear with increased risk at Lp(a) values ≥30 48 
mg/dL  or  aseline Lp(a) and ≥50 mg/dL  or on-statin Lp(a). Age- and sex-adjusted hazard 49 
ratios across Lp(a) groups [referent: Lp(a) <15 mg/dL] were 1·04 (0·91, 1·18), 1·11 (1·00, 50 
1·22), and 1·31 (1·08, 1·58) for baseline Lp(a), and 0·94 (0·81, 1·10), 1·06 (0·94, 1·21), and 51 
1·43 (1·15, 1·76) for on-statin Lp(a). Hazard ratios were virtually identical after further 52 
adjustment for prior CVD, diabetes, smoking, systolic blood pressure, low-density-53 
lipoprotein cholesterol, and high-density-lipoprotein cholesterol. The association of on-statin 54 
Lp(a) with CVD risk was stronger than for on-placebo Lp(a) (interaction P=0·010) and was 55 
more pronounced at younger ages (interaction P=0·008) without effect modification by any 56 
other patient-level or study-level characteristics.  57 
Interpretation: In this individual-patient meta-analysis of statin-treated patients, elevated 58 
baseline and on-statin Lp(a) showed an independent, approximately linear relationship with 59 
CVD risk. This study provides a rationale for testing the Lp(a) lowering hypothesis in CVD 60 
outcomes trials.  61 
Funding: Novartis Pharma AG provided support for the performance of the meta-analysis. 62 
 63 
  64 
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Introduction 65 
Lipoprotein(a) [Lp(a)] is a lipoprotein composed of apolipoprotein(a) covalently bound to 66 
apolipoprotein B (apoB) of a low-density lipoprotein (LDL) like particle.
1,2
 Lp(a) mediates 67 
atherogenicity via its LDL moiety that has a similar proportion of cholesterol content as 68 
traditional LDL particles. In addition, it induces pro-inflammatory responses
3,4
 via 69 
accumulation of oxidised phospholipids
5
 and potentially exerts pro-thrombotic effects via the 70 
plasminogen-like apolipoprotein(a) moiety.
6
 In contrast to other major lipoproteins, there is 71 
no approved specific therapy to lower circulating plasma levels of Lp(a).   72 
Epidemiologic
7
 and genetic
8,9
 evidence has accumulated over the last decade showing that 73 
elevated Lp(a), driven primarily by the LPA gene,
10
 is associated with increased risk of 74 
coronary  heart disease, stroke, peripheral arterial disease, and calcific aortic valve 75 
stenosis.
1,2,11
 These data have established Lp(a) as a cardiovascular disease (CVD) risk factor, 76 
but the bulk of evidence is based on studies involving individuals without prior CVD and 77 
without intensive secondary prevention therapies. In contrast, the role of elevated Lp(a) in 78 
patients with prior CVD events or on statin therapy and other guideline-recommended 79 
therapies is less clear. Prior studies in this patient population yielded inconsistent results, with 80 
findings ranging from significant positive associations to null associations such as following 81 
acute coronary syndromes (reviewed in reference
2
). In addition, several studies, including 82 
JUPITER
12
 and AIM-HIGH
13
, have shown that elevated Lp(a) remain predictive for CVD 83 
risk at LDL-cholesterol (LDL-C) levels <70 mg/dL,
1
 but other studies suggest a positive 84 
association only when LDL-C is elevated.
14
 Furthermore, a major limitation of all post hoc 85 
studies reporting Lp(a) levels and outcomes is that they involved only a small number of 86 
patients with Lp(a) values above 50 mg/dL and therefore were uniformly underpowered to 87 
test the hypothesis that elevated Lp(a) levels are associated with increased CVD risk in the 88 
setting of statin therapy or prior history of CVD. 89 
To test this hypothesis with adequate statistical power, we established the Lipoprotein(a) 90 
Studies Collaboration, a consortium of patient-level data from placebo-controlled trials of 91 
statins with patient-level data on CVD outcomes and Lp(a) measurements at baseline and 92 
follow-up (i.e. under statin treatment). We now report the results of this analysis in 93 
documenting the associations of baseline and on-treatment Lp(a) with cardiovascular risk.  94 
Methods 95 
Trials included in the meta-analysis 96 
To be eligible in the meta-analysis, randomized placebo-controlled statin trials were required 97 
to have assayed Lp(a) concentration at baseline and follow-up, have recorded incidence of 98 
CVD outcomes using well-defined criteria, and be willing to share patient data at the 99 
individual-level. We included data from AFCAPS, CARDS, 4D, JUPITER, LIPID, 100 
MIRACL, and 4S. Their study design, target population, and entry criteria are summarised in 101 
Table 1; more detailed descriptions of trial designs
15–21
 and Lp(a) methodology and data
12,22–
102 
26
 were previously reported by each trial. Trials not included in the meta-analysis were either 103 
not allowed or willing to provide individual-level patient data. Due to contractual agreements 104 
on sharing individual patient data, other eligible trials could not be included in the meta-105 
analysis. All contributing trials have o tained ethi s approval and patients’ in ormed  onsent. 106 
Statistical analyses 107 
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Analyses were conducted according to a pre-specified analysis plan, developed prior to any 108 
combined analyses. Lp(a) values were loge-transformed. Of 45044 patients enrolled in the 109 
seven trials, 15975 (35·5%) patients were excluded because of missing Lp(a) measurements 110 
at both baseline and follow-up, leaving 29069 patients for analysis (for CONSORT diagram, 111 
please refer to Supplementary Figure 1). There were minimal differences in baseline 112 
characteristics of patients with or without available Lp(a) measurements (Supplementary 113 
Table 1). In all trials except 4S, on-statin Lp(a) during follow-up was measured at one time-114 
point. In the 4S trial, on-statin Lp(a) was estimated as the geometric mean of Lp(a) values 115 
assessed at up to four distinct time points. Lp(a) values provided in nmol/L were divided by 116 
2·4 (JUPITER), as previously described
27
, and those provided in IU/L by 19·07 (4S) to 117 
convert them to the common unit of mg/dL. When information on Lp(a) was missing either at 118 
baseline (0·5%) or at follow-up (5·5%), their Lp(a) value was mean-imputed from study-119 
specific mixed-effects models which predicted Lp(a) values using fixed effects for assigned 120 
treatment, time-in-study, and the interaction of the two variables, plus a random intercept 121 
allowed to vary at the patient level.  122 
Because  onventional “L L- ” assa s  apt re  holesterol both in LDL and Lp(a) particles, 123 
LDL-C values were corrected for the latter. Lp(a) mass in mg/dL is composed of ~30-45% 124 
cholesterol.
28
 We used a conservative measurement of the content of Lp(a)-C by multiplying 125 
Lp(a) mass (in mg/dL) by 0·30 to derive Lp(a)-cholesterol, and then subtracting this value 126 
from the measured LDL-C to obtain corrected LDL-C (LDL-Ccorr).
28
  127 
The combined CVD endpoint was defined as the occurrence of fatal or non-fatal coronary 128 
heart disease, stroke, or any coronary or carotid revascularisation procedures. In analysing 129 
on-treatment Lp(a), all CVD events that occurred after randomisation were considered 130 
because any change in Lp(a) under statin therapy is anticipated to occur within a short time 131 
period (sensitivity analyses omitted the initial period of follow-up).
12
  132 
Associations of Lp(a) with CVD risk were estimated using a two-step approach, with 133 
estimates calculated within each study separately before pooling them across studies using 134 
multivariate random-effects meta-analysis.
29
 Hazard ratios were calculated using Cox 135 
proportional hazard regression models which used time-on-study as a timescale, were 136 
stratified by trial arm, and compared the pre-specified Lp(a) groups <15 mg/dL, 15-<30 137 
mg/dL, 30-<50 mg/dL, and ≥50 mg/dL. The assumption for the proportionality of hazards 138 
was tested using Schoenfeld residuals and was met. The analysis had four inter-related 139 
principal aims. First, to evaluate shapes of associations, pooled hazard ratios were calculated 140 
over Lp(a) groups and plotted against the pooled geometric mean of Lp(a) concentration 141 
within each category.
29
 Second, to determine the extent of confounding, hazard ratios were 142 
progressively adjusted for age, sex, prior CVD, diabetes, smoking, systolic blood pressure, 143 
LDL-Ccorr, and high-density-lipoprotein-cholesterol (“m ltivaria le adjusted model”). Further 144 
adjustment for body-mass index and estimated glomerular filtration rate was employed in the 145 
subset of patients, in which these data were available. Third, to investigate whether the 146 
predictive value of follow-up Lp(a) differed between patients randomized to statin vs. 147 
placebo, interaction models by trial arm were fitted. Fourth, to investigate effect modification 148 
by individual-patient and study-level characteristics, formal tests of interaction and meta-149 
regression analyses with these variables were performed. There was little variability within 150 
each trial of the proportion of patients with prior CVD and with a history of diabetes at 151 
baseline (e.g. secondary vs. primary CVD prevention trials, diabetes as inclusion or exclusion 152 
criterion) and hence effect modification by these characteristics was investigated at the study-153 
level instead of at the patient-level. Between-trial heterogeneity was assessed with the I
2
 154 
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statistic.
30
 Analyses were performed using Stata (version 14·1 MP) and involved two-sided 155 
statistical tests and 95% confidence intervals. Principal analyses used a significance level of 156 
P<0·05 and subgroup analyses a Bonferroni-corrected significance level of P<0·007 (for 157 
seven subgroups). 158 
Role of funding source 159 
The funders of the study had no role in study design, data collection, data analysis, data 160 
interpretation, or writing of the report. PW and ST had full access to all the data in the study 161 
and had final responsibility for the decision to submit for publication.  162 
Results 163 
Summary of available data 164 
Data on 29069 patients from seven contributing trials were analysed (Table 2). At trial entry, 165 
mean age was 62 years (SD 8), 8064 were female (28%), 15252 had prior CVD (52%), 5177 166 
had diabetes (18%), 4847 were current smokers (17%), mean systolic blood pressure was 137 167 
mmHg (SD 18), and mean LDL-Ccorr was 3·30 mmol/L (SD 0·67). Median concentration of 168 
Lp(a) at baseline was in low normal range of 11 mg/dL (interquartile range: 5-29). In cross-169 
sectional analyses, baseline Lp(a) concentration was higher in females (+12% [3, 21]), lower 170 
in patients with diabetes (-17% [-24, -9]) and unrelated to smoking (+2% [-3, 8]). 171 
Furthermore, LDL-Ccorr, loge triglycerides, body-mass index, and systolic blood pressure 172 
were associated with a lower and HDL-C with a higher Lp(a) concentration (age-and sex-173 
adjusted differences in Lp(a) per SD: -16% [-23, -8], -12% [-15, -9], -7% [-10, -5], -2% [-5, -174 
0], and +7% [3, 11]). Baseline Lp(a) was not associated with age (-1% [-2, 1] per SD).  175 
A total of 14536 patients were randomized to receive statin therapy (Table 2). Initiation of 176 
statin therapy reduced LDL-Ccorr by -39% (95% confidence interval: -43, -35). The effect of 177 
statin on Lp(a) concentration was heterogeneous across trials; the pooled percentage change 178 
was -0·4% (-7, 7), with three trials showing a mean increase (range +2 to +15%) and four 179 
trials showing a mean decrease (range -1 to -13%) in Lp(a). The median concentration of 180 
Lp(a) on statin therapy was 11 mg/dL (interquartile range: 5-32). The age- and sex-adjusted 181 
correlation between baseline and follow-up loge Lp(a) was comparable in the statin arm and 182 
the placebo arm (r=0.948 vs. 0.952). 183 
Associations of baseline and on-statin Lp(a) with cardiovascular disease risk 184 
During 95576 person-years at risk (median follow-up 3·0 years [interquartile range: 1·5-185 
5·3]), a total of 5751 CVD events were recorded, of which 2603 occurred in the statin arm 186 
(Table 2). When patients were grouped by Lp(a) concentration into the categories <15 187 
mg/dL, 15-<30 mg/dL, 30-<50 mg/dL, and ≥50 mg/dL, in idence rates for CVD (95% CI) 188 
per 1000 person-years were as follows: 55·3 (53·4-57·3), 56·3 (52·6-60·2), 66·7 (62·0-71·8), 189 
and 80·0 (75·3-84·9) for baseline Lp(a), and 49·0 (46·5-51·6), 46·4 (41·6-51·7), 56·2 (50·3-190 
62·8), and 77·2 (71·1-83·8) for on-statin Lp(a). 191 
In analyses adjusted for age and sex only, associations of baseline and on-statin Lp(a) values 192 
with the risk of CVD were of positive approximately linear shape, with a possible threshold 193 
effect in the group with Lp(a) values of 50 mg/dL or more (Figure 1). For baseline Lp(a), the 194 
hazard ratios compared to patients with Lp(a) values of <15 mg/dL were 1·04 (0·91, 1·18) 195 
with Lp(a) values 15-<30 mg/dL, 1·11 (1·00, 1·22) with Lp(a) values 30-<50 mg/dL, and 196 
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1·31 (1·08, 1·58) with Lp(a) values ≥50 mg/dL (Table 3). For on-statin Lp(a), corresponding 197 
hazard ratios were 0·94 (0·81, 1·10), 1·06 (0·94, 1·21), and 1·43 (1·15, 1·76).  198 
Associations remained robust to additional adjustment for prior CVD, diabetes, smoking, 199 
systolic blood pressure, LDL-Ccorr, and HDL-C concentration (Figure 1 and Table 3). 200 
Corresponding hazard ratios were 1·04 (0·91, 1·20), 1·13 (1·02, 1·25), and 1·35 (1·11, 1·66) 201 
for baseline Lp(a) and 0·95 (0·82, 1·11), 1·08 (0·95, 1·23), and 1·42 (1·16, 1·74) for on-202 
statin Lp(a). In a sensitivity analysis of patients with information on triglycerides, body-mass 203 
index, or estimated glomerular filtration rate, further adjustment for these parameters did not 204 
materially change the magnitude of association between Lp(a) measurements and CVD risk 205 
(Supplementary Table 2). Effect sizes comparable with those in the principal analysis were 206 
observed when further categorising the highest Lp(a) group into patients with levels 50-<75 207 
mg/dL and ≥75 mg/dL (Supplementary Table 3) and in the on-statin analysis when omitting 208 
events that occurred in the initial period between randomization and on-statin measurement 209 
of Lp(a) (Supplementary Table 4). Trial-specific findings are provided in Supplementary 210 
Table 5. 211 
Comparative predictive value of on-statin vs. on-placebo Lp(a) 212 
Lp(a) concentration measured during follow-up was more strongly associated with CVD risk 213 
in the on-statin arm than in the on-placebo arm (Figure 2). In comparison of patients with 214 
Lp(a) ≥50 mg/dL with those having Lp(a) <50 mg/dL, the age- and sex-adjusted hazard ratios 215 
for CVD were 1·48 (1·23 to 1·78) for on-statin Lp(a) and 1·23 (1·04 to 1·45) for on-placebo 216 
Lp(a) (interaction P=0·010). The corresponding multivariable adjusted hazard ratios were 217 
1·47 (1·25 to 1·73) and 1·26 (1·06 to 1·50) (interaction P=0·031). The median time from 218 
randomization to Lp(a) repeat was 1.0 years in both trial arms. 219 
Associations according to patient-level and study-level characteristics 220 
There was some heterogeneity between trials in hazard ratios for CVD, most pronounced in 221 
the group with a Lp(a) concentrations ≥50 mg/dL. For example, in this group, I2 values of 222 
age- and sex-adjusted hazard ratios were 73% (43, 88) for baseline Lp(a) and 62% (13, 83) 223 
for on-statin Lp(a) (Table 3). Apart from stronger associations of on-statin Lp(a) with CVD 224 
risk at younger age (<60 years vs. 60-<70 years vs. ≥70 years; interaction P=0·008), hazard 225 
ratios did not vary significantly across clinically relevant subgroups, such as by sex, smoking, 226 
systolic blood pressure, lipid parameters, or body-mass index (Figure 3). Furthermore, the 227 
magnit de o  asso iation was independent o  a st d ’s proportion o  patients with prior  V  228 
or diabetes, the length of follow-up for clinical events, and the time between study baseline 229 
and follow-up on-statin Lp(a) measurement (Supplementary Figure 2). Contributing trials 230 
employed differing statin interventions, precluding a subgroup analysis by statin type or 231 
statin dosage.  232 
Discussion 233 
This well-powered meta-analysis of Lp(a) and CVD events reveals that patients with elevated 234 
Lp(a) on statin therapy, primarily with levels of >50 mg/dL, are at a significantly higher risk 235 
of CVD. The association with CVD risk was independent of conventional CVD risk factors, 236 
as also reflected in the very weak or null cross-sectional correlations of Lp(a) with these risk 237 
factors. Importantly, hazard ratios for high Lp(a) at baseline and under statin therapy were of 238 
similar magnitude, reflecting that statin therapy may not appreciably affect Lp(a)-mediated 239 
risk in patients with elevated Lp(a). Overall, these data suggest that patients with elevated 240 
 - 7 - 
 
Lp(a), representing ~25% of subjects with prior CVD or statin indication,
1
 are at substantial 241 
residual risk even under statin therapy. In this patient population, therapies which specifically 242 
lower Lp(a) might mitigate Lp(a)-mediated risk. An appropriately designed CVD outcomes 243 
trial with robust Lp(a)-lowering is therefore justified to test the hypothesis that lowering 244 
Lp(a) reduces CVD events, independent of statin treatment.  245 
At baseline, Lp(a) levels were weakly associated with demographic and laboratory variables. 246 
The most significant but nevertheless weak correlations were inverse with diabetes mellitus 247 
and triglycerides. The observation of an inverse association of Lp(a) with incident diabetes 248 
has been made previously,
31
 and is most pronounced at very low levels of Lp(a) (5 mg/dL), 249 
which are present in the 10th percentile of the global population.
1,2
 It has not been determined 250 
if the findings are causal or if there is confounding by reverse causality.
32
 Although the 251 
underlying mechanisms are not well understood, fasting and post-prandial insulin levels are 252 
inversely associated with Lp(a).
33
 Lp(a) was weakly correlated with LDL-C, but this 253 
relationship became inversely associated after subtracting the estimated cholesterol content in 254 
Lp(a) from the laboratory measurement called “L L- ”.28  255 
Prior studies evaluating the role of Lp(a) in predicting CVD in patients without CVD, using 256 
Lp(a) assays in the modern era that lack limitations of prior assays, have been almost 257 
uniformly positive.
7
 However, studies in patients with prior CVD or on statin therapy have 258 
been mixed, or have suggested the effect is present primarily in patients with elevated LDL-C 259 
(reviewed in Tsimikas et al.
2
). A major limitation of all substudies reporting Lp(a) and 260 
outcomes has been power. All studies have enrolled patients with Lp(a) levels in the mid to 261 
low normal range (10-15 mg/dL, normal <30 mg/dL), as confirmed in the current meta-262 
analysis, thus statistical power to evaluate risk in patients with highly elevated Lp(a) (i.e. >50 263 
mg/dL) was limited. The current study is highly powered with 5751 total events and 2603 264 
events in the statin arms, making it equivalent to, or larger than, most individual randomised 265 
controlled cardiovascular outcome trials in the modern era. In contrast to a previous analysis 266 
of individual-patient data    O’ onogh e et al,34 our study afforded higher statistical power 267 
because it involved >10 times more CVD events, and hence was able to characterise 268 
associations with high Lp(a) concentrations more precisely. Moreover, the present analysis 269 
used clinically-relevant Lp(a) categories informed by guideline recommendations, as opposed 270 
to trial-specific quintiles. 271 
The current meta-analysis is also highly representative of clinical care in patients treated with 272 
statins. First, these studies represent patients who were treated with moderate-high doses of 273 
the five major statins used clinically. Second, they reflect the variety of patients treated 274 
clinically, including primary prevention, high-risk primary prevention with elevated C-275 
reactive protein or diabetes, secondary prevention, stable coronary artery disease, acute 276 
coronary syndromes, patients on dialysis and highly elevated LDL-C in the familial 277 
hypercholesterolemia range. Therefore, they broadly reflect patients with high residual risk 278 
despite statin treatment, potentially due to other, unmodified risk factors such as elevated 279 
Lp(a). 280 
The risk thresholds chosen reflect clinical risk as suggested by epidemiologic and genetic 281 
studies. The reference cutoff of <15 mg/dL, reflects roughly the median global level of 282 
Lp(a).
35,36
 Lp(a) <30 mg/dL represents the usual cutoff in US laboratories that is considered 283 
as normal level, and is based on data showing that risk of myocardial infarction starts to 284 
accrue at levels above 25-30 mg/dL.
7,37
 The range of 30-50 mg/dL was chosen as this is the 285 
grey zone between what is considered pathophysiologically relevant and >50 mg/dL is based 286 
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on what the European Atherosclerosis Society as considered elevated levels at highest risk 287 
based on the European population prevalence of 20%.  288 
In this study, elevation of CVD risk became evident at baseline Lp(a) 30 to <50 mg/dL and 289 
was further pronounced when Lp(a) levels exceeded 50 mg/dL, including patients treated 290 
with statins. The hazard ratios for Lp(a) ≥50 mg/dL are consistent with recent PCSK9 291 
inhibitor studies in patients with background statin therapy.
38
 Additional analyses at even 292 
higher Lp(a), i.e. ≥75 mg/dL were limited by low power due to small numbers of patients 293 
with Lp(a) levels in this range, but support a graded relationship of Lp(a) with cardiovascular 294 
risk. Outcome trials of Lp(a) lowering are likely to include patients with mean baseline Lp(a) 295 
substantially >50 mg/dL, therefore, extrapolation to event reduction with Lp(a) lowering 296 
from these data may be an underestimate. 297 
A key observation of this study is that on-statin Lp(a) was more strongly associated with 298 
CVD risk than on-placebo Lp(a). A small angiographic study initially suggested that the risk 299 
of Lp(a) is attenuated when LDL-C is well controlled.
39
 In contrast, the current study, 300 
utilising a far larger body of data, supports the opposite conclusion that risk is independently 301 
associated with both LDL-C and Lp(a). When LDL-attributable risk is reduced with statin 302 
treatment, Lp(a)-associated risk becomes an even stronger predictor of residual risk. This 303 
observation is particularly evident at Lp(a) levels exceeding 50 mg/dL. In support of our 304 
observation in this study, the trials FOURIER (European Atherosclerosis Society, May 2018) 305 
and ODYSSEY OUTCOMES (International Atherosclerosis Society, June 2018) have 306 
recently presented preliminary findings of their data, both showing that elevated baseline 307 
Lp(a) remains a risk factor even with on-treatment LDL-C <50 mg/dL in patients treated with 308 
statins and PCSK9 inhibitors. The findings raise the importance of determining whether there 309 
is a cardiovascular benefit of treatment to reduce Lp(a) when initial levels exceed this 310 
threshold, irrespective of concurrent treatment with statin. A second important observation is 311 
that all major subgroups of patients seemed to be at risk of elevated Lp(a), including those 312 
>70 years old, females, smokers, those with low and high LDL-Ccorr, low HDL-C and all 313 
categories of body-mass index.  314 
It is important to emphasize that the Lp(a) hypothesis remains to be tested. To do so requires 315 
a randomized trial that compares cardiovascular outcomes in patients treated with an agent 316 
that specifically lowers Lp(a) versus placebo. Such a trial may be possible with antisense 317 
oligonucleotide targeting LPA messenger RNA, thereby reducing plasma Lp(a) levels. Phase 318 
I and II trials with this agent have shown the potential to lower Lp(a) levels by over 90% 319 
without major effects on other classes of lipoproteins.
27,40
  320 
One limitation of this study is that individual-patient data could not be obtained from several 321 
other statin trials that reported Lp(a) levels and outcomes. It is possible that inclusion of other 322 
data would have modified the observed effect sizes. Secondly, the relationship of Lp(a) to 323 
residual cardiovascular risk under treatment with non-statin lipid-modifying agents (e.g., 324 
ezetimibe, PCSK9 inhibitors) remains undetermined. Third, the Lp(a) assays were 325 
heterogeneous and most were in Lp(a) mass rather than in Lp(a) molar concentration and the 326 
timepoints at which they were measured in each trial were not uniform. Therefore, the assays 327 
not reported in mg/dL had to be mathematically converted to mg/dL, which may have 328 
introduced imprecision into the Lp(a) measurement. A recent NHLBI Working Group on 329 
Lp(a) recommended global standardization of Lp(a) assays to address this limitation.
2
 Fourth, 330 
we cannot rule out that index event bias may have attenuated effect sizes in secondary 331 
prevention trials, although the scope of this bias was reduced by employment of multivariable 332 
adjustment. Fifth, our analysis identified moderate to high between-study heterogeneity, 333 
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which could not be explained by baseline disease status (i.e. prior CVD or prior diabetes) nor 334 
by differing lengths of follow-up periods. Finally, the data for the change in Lp(a) post statin 335 
therapy was heterogeneous across studies, with both increases and decreases, but no net 336 
change. Due to different assays used in each of the trials, and the need for conversion of all 337 
data to mg/dL, and the higher precision required to show intra-individual changes, these data 338 
should be considered hypothesis generating. A more robust test of this particular hypothesis 339 
should ideally be performed using the same assay. 340 
In conclusion, this meta-analysis demonstrates an approximately linear relationship of 341 
cardiovascular risk to levels of Lp(a), evident at Lp(a) levels 30-50 mg/dL, pronounced at 342 
levels ≥50 mg/dL, and persisting despite statin treatment. These data provide a rationale for 343 
evaluating drugs that can specifically lower Lp(a) and might have the potential to reduce 344 
residual cardiovascular risk independent of statin treatment. 345 
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Research in context  498 
Evidence before this study:  Lp(a) has been associated with increased risk of incident 499 
cardiovascular disease in primary care populations, but its role in predicting cardiovascular 500 
events in high-risk patients treated with statins is unclear. We searched PubMed for relevant 501 
clinical trials published up to July 9, 2018, using the search terms "Lipoprotein(a)" or 502 
"Lp(a)", plus “statin” and "cardiovascular diseases"[MeSH]. Our review identified seven 503 
statin trials (4D, 4S, FLARE, JUPITER, LIPID, MIRACL, and TNT), which reported on the 504 
association of Lp(a) with cardiovascular risk. The interpretation of the available evidence is 505 
complicated by inconsistent findings across trials (positive vs. null associations), limited 506 
statistical power of single trials, limited availability of follow-up Lp(a) measurements, and 507 
differing definitions of Lp(a) categories across trials. 508 
Added value of this study:  We obtained patient-level data in seven placebo-controlled 509 
statin trials encompassing 29069 patients and analysed the relationship of baseline and on-510 
treatment Lp(a) to risk of major adverse cardiovascular events. Elevated Lp(a) of 50 mg/dL 511 
or higher, at baseline or on-treatment, was associated with an increased hazard ratio of 512 
cardiovascular events independent of other cardiovascular risk factors and evident on 513 
treatment with either statin or placebo.  514 
Implications of all the available evidence:  These data suggest that residual risk is present 515 
in patients with elevated Lp(a) that is not addressed by statins and supports the rationale for 516 
outcomes trials to test specific therapies to lower Lp(a). 517 
  518 
 - 14 - 
 
Tables 519 
 520 
Table 1 – Design features of contributing trials. 521 
Cohort 
Years of 
baseline 
Target population Lipid entry criteria, mmol/L 
Comparator to 
placebo 
CVD outcome 
definition 
M
I 
S
ta
b
le
 a
n
g
in
a
 
S
tr
o
k
e 
R
ev
a
sc
u
la
ri
sa
ti
o
n
 
O
th
er
 
AFCAPS15 1990-1993 Primary prevention TC 4·65-6·82, LDL-C 3·36-
4·9 , TG ≤4·52, HDL-C 
≤ · 6♂ and ≤ ·22♀ 
Lovastatin 20mg ● ● ● ● ●* 
CARDS22 1997-2001 Type 2 diabetes LDL-  ≤4· 4, TG ≤6·78 Atorvastatin 10mg ● ○ ● ● ○ 
4D23 1998-2002 Type 2 diabetes + 
hemodialysis 
LDL-C 2·07-4·92, TG ≤  ·3 Atorvastatin 20mg ● ○ ● ● ○ 
JUPITER12 2003-2006 Primary prevention 
with C-reactive 
protein >2mg/dL 
LDL-C <3·4, TG <5·65 Rosuvastatin 20mg ● ○ ● ● ●† 
LIPID24 1990-1992 Prior myocardial 
infarction or unstable 
angina 
TC 4·0-7·0, TG <5·0 Pravastatin 40mg ● ○ ● ● ○ 
MIRACL25 1997-1999 Acute coronary 
syndrome 
TC <7·0 Atorvastatin 80mg ● ○ ● ● ○ 
4S26 1989-1990 Prior myocardial 
infarction or angina 
TC 5·5-8·0, TG ≤2·5 Simvastatin 20mg ● ○ ○ ● ○ 
AFCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study. CARDS=Collaborative Atorvastatin Diabetes 522 
Study. CVD=cardiovascular disease. 4D=Die Deutsche Diabetes-Dialyse-Studie. HDL-C=high-density lipoprotein 523 
cholesterol. JUPITER=Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin. 524 
LDL-C=low-density lipoprotein cholesterol. LIPID=Long-Term Intervention with Pravastatin in Ischaemic Disease. 525 
MI=myocardial infarction. MIRACL=Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. 526 
4S=Scandinavian Simvastatin Survival Study. TC=total cholesterol. TG=triglycerides. *Transient ischemic attack, peripheral 527 
vascular disease, sudden death, and deaths from other cardiovascular causes. †Deaths from other cardiovascular causes. 528 
  529 
 - 15 - 
 
Table 2 – Patient characteristics. 530 
  AFCAPS CARDS 4D JUPITER LIPID MIRACL 4S Total 
Baseline   
      
No. of patients 1005 2470 1249 9612 7863 2431 4439 29069 
Lp(a), mg/dL, median (IQR) 7 (3-17) 9 (5-22) 12 (5-42) 11 (5-23) 14 (7-44) 10 (5-29) 10 (4-28) 11 (5-29) 
<15 mg/dL 733 (73) 1658 (67) 709 (57) 5896 (61) 4118 (52) 1481 (61) 2654 (60) 17249 (59) 
15-<30 mg/dL 134 (13) 310 (13) 129 (10) 1867 (19) 1147 (15) 362 (15) 781 (18) 4730 (16) 
30-<50 mg/dL 84 (8) 212 (9) 140 (11) 851 (9) 877 (11) 223 (9) 714 (16) 3101 (11) 
≥50 mg/dL 54 (5) 290 (12) 271 (22) 998 (10) 1721 (22) 365 (15) 290 (7) 3989 (14) 
Age, yrs 59 (7) 62 (8) 66 (8) 66 (8) 61 (8) 65 (11) 59 (7) 62 (8) 
Female sex 173 (17) 779 (32) 576 (46) 3556 (37) 1333 (17) 820 (34) 827 (19) 8064 (28) 
Prior CVD 0 (0) 6 (0) 513 (41) 0 (0) 7863 (100) 2431 (100) 4439 (100) 15252 (52) 
Diabetes 32 (3) 2470 (100) 1249 (100) 0 (0) 676 (9) 548 (23) 202 (5) 5177 (18) 
Current smoking 130 (13) 551 (22) 108 (9) 1492 (16) 735 (9) 693 (29) 1138 (26) 4847 (17) 
SBP, mmHg 136 (17) 144 (16) 146 (22) 136 (17) 134 (19) 128 (20) 139 (20) 137 (18) 
LDL-Ccorr, mmol/L – 2·75 (0·78) 3·00 (0·86) 2·57 (0·49) 3·68 (0·74) 3·04 (0·86) 4·74 (0·66) 3·30 (0·67) 
HDL-C, mmol/L – 1·64 (0·50) 0·94 (0·34) 1·35 (0·40) 0·96 (0·24) 1·20 (0·31) 1·19 (0·30) 1·21 (0·35) 
BMI, kg/m² 26 (3) 29 (4) 28 (5) 29 (6) – 28 (5) 26 (3) 28 (5) 
eGFR, mL/min – – – 75 (17) 71 (17) – – 73 (17) 
Apo-B, g/L – 1·16 (0·24) 1·10 (0·30) 1·08 (0·21) 1·33 (0·25) – 1·16 (0·18) 1·17 (0·23) 
On-statin 
        
No. of patients 504 1255 616 4802 3941 1200 2218 14536 
Time to Lp(a) repeat, yrs, median 1·0 2·5 0·5 1·0 1·0 0·2 2·5 1·0 
Lp(a), mg/dL, median (IQR) 7 (3-19) 8 (4-22) 11 (5-40) 11 (4-25) 13 (6-43) 11 (5-33) 11 (4-33) 11 (5-32) 
<15 mg/dL 366 (73) 864 (69) 351 (57) 2912 (61) 2106 (53) 707 (59) 1268 (57) 8574 (59) 
15-<30 mg/dL 59 (12) 134 (11) 60 (10) 868 (18) 548 (14) 175 (15) 321 (15) 2165 (15) 
30-<50 mg/dL 43 (9) 103 (8) 73 (12) 417 (9) 439 (11) 96 (8) 375 (17) 1546 (11) 
≥50 mg/dL 36 (7) 154 (12) 132 (21) 605 (13) 848 (22) 222 (19) 254 (12) 2251 (15) 
% change vs. baseline (95% CI) -1% (-6, 4) -13% (-15, -10) -6% (-9, -3) 2% (1, 3) -7% (-8, -5) 9% (6, 12) 15% (13, 17) -0·4% (-7, 7) 
LDL-Ccorr, mmol/L – 1·68 (0·58) 1·73 (0·78) 1·43 (0·70)  2·57 (0·71) 1·56 (0·77) 2·97 (0·70) 1·99 (0·70) 
% change vs. baseline (95% CI) – -37% (-38, -36) -41% (-43, -39) -43% (-44, -42) -29% (-30, -29) -47% (-49, -46) -37% (-37, -36) -39% (-43, -35) 
CVD incidence 
        
Follow-up, yrs, median (IQR) 5·6 (4·8-6·2) 4·1 (3·1-4·8) 2·4 (1·4-3·7) 2·0 (1·5-2·4) 5·4 (3·1-6·0) 0·3 (0·3-0·3) 5·3 (3·9-5·5) 3·0 (1·5-5·3) 
No. of events, overall 68 170 338 234 3040 537 1364 5751 
No. of events, statin arm 31 71 166 81 1428 258 568 2603 
Mean (SD) or n (%), unless stated otherwise. Percentages may not sum up to 100% due to rounding. For full trial names, refer to footnote of Table 1. Total means (standard 531 
deviations) and % changes (95% confidence intervals) were calculated by pooling study-specific estimates with random-effects meta-analysis. Apo-B=apolipoprotein B. 532 
BMI=body-mass index. CVD=cardiovascular disease. eGFR=estimated glomerular filtration rate. HDL-C=high-density lipoprotein cholesterol. IQR=interquartile-range. LDL-533 
Ccorr=low-density lipoprotein cholesterol corrected for Lp(a)-cholesterol. SBP=systolic blood pressure.  534 
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Table 3 – Associations of baseline and on-statin Lp(a) with incident cardiovascular disease according to different levels of adjustment. 535 
Lp(a) measurement / 
adjustment 
Lp(a) 15-<30 mg/dL 
 
Lp(a) 30-<50 mg/dL 
 
Lp(a) ≥50 mg/dL 
 
HR (95% CI)* P value I2 (95% CI)  HR (95% CI)* P value I2 (95% CI)  HR (95% CI)* P value I2 (95% CI) 
Baseline Lp(a) 
Basic adjustment: 7 trials – 29069 patients – 5751 events  
Age- and sex-adjusted 1·04 (0·91, 1·18) 0·59 43% (0, 76)  1·11 (1·00, 1·22) 0·047 0% (0, 71)  1·31 (1·08, 1·58) 0·005 73% (43, 88) 
Progressive adjustment: 6 trials – 27764 patients – 5649 events  
Age- and sex-adjusted 1·03 (0·90, 1·18) 0·64 54% (0, 81)  1·10 (1·00, 1·22) 0·053 0% (0, 75)  1·30 (1·06, 1·59) 0·010 78% (52, 90) 
  Plus prior CVD 1·04 (0·90, 1·19) 0·61 53% (0, 81)  1·10 (1·00, 1·22) 0·049 0% (0, 75)  1·31 (1·07, 1·60) 0·009 78% (52, 90) 
  Plus diabetes 1·04 (0·91, 1·19) 0·60 52% (0, 81)  1·11 (1·01, 1·23) 0·036 0% (0, 75)  1·32 (1·08, 1·61) 0·007 78% (51, 90) 
  Plus smoking 1·03 (0·91, 1·18) 0·61 50% (0, 80)  1·11 (1·01, 1·22) 0·034 0% (0, 75)  1·31 (1·08, 1·59) 0·007 77% (48, 90) 
  Plus SBP 1·03 (0·90, 1·18) 0·64 53% (0, 81)  1·11 (1·01, 1·22) 0·031 0% (0, 75)  1·31 (1·07, 1·59) 0·008 77% (49, 90) 
  Plus LDL-Ccorr 1·04 (0·90, 1·19) 0·61 55% (0, 82)  1·12 (1·02, 1·24) 0·019 0% (0, 75)  1·34 (1·09, 1·65) 0·005 78% (53, 90) 
  Plus HDL-C 1·04 (0·91, 1·20) 0·54 54% (0, 82)  1·13 (1·02, 1·25) 0·016 0% (0, 75)  1·35 (1·11, 1·66) 0·003 77% (49, 90) 
On-statin Lp(a) 
Basic adjustment: 7 trials – 14536 patients – 2603 events  
Age- and sex-adjusted 0·94 (0·81, 1·10) 0·45 18% (0, 62)  1·06 (0·94, 1·21) 0·33 0% (0, 71)  1·43 (1·15, 1·76) 0·001 62% (13, 83) 
Progressive adjustment: 6 trials – 13883 patients – 2561 events  
Age- and sex-adjusted 0·93 (0·79, 1·09) 0·37 18% (0, 63)  1·06 (0·93, 1·21) 0·35 0% (0, 75)  1·39 (1·12, 1·72) 0·002 64% (13, 85) 
  Plus prior CVD 0·93 (0·79, 1·09) 0·37 18% (0, 63)  1·06 (0·93, 1·21) 0·36 0% (0, 75)  1·39 (1·12, 1·72) 0·002 64% (13, 85) 
  Plus diabetes 0·94 (0·80, 1·10) 0·43 17% (0, 62)  1·07 (0·94, 1·22) 0·31 0% (0, 75)  1·39 (1·13, 1·71) 0·002 62% (7, 84) 
  Plus smoking 0·94 (0·81, 1·09) 0·42 8% (0, 77)  1·07 (0·94, 1·22) 0·30 0% (0, 75)  1·39 (1·13, 1·71) 0·002 62% (8, 84) 
  Plus SBP 0·94 (0·81, 1·09) 0·41 9% (0, 77)  1·07 (0·94, 1·22) 0·30 0% (0, 75)  1·39 (1·13, 1·71) 0·002 61% (6, 84) 
  Plus LDL-Ccorr 0·94 (0·81, 1·10) 0·47 13% (0, 78)  1·08 (0·95, 1·23) 0·26 0% (0, 75)  1·41 (1·15, 1·73) 0·001 61% (3, 84) 
  Plus HDL-C 0·95 (0·82, 1·11) 0·53 13% (0, 78)  1·08 (0·95, 1·23) 0·24 0% (0, 75)  1·42 (1·16, 1·74) 0·001 58% (0, 83) 
CI=confidence interval. CVD=cardiovascular disease. HDL-C=high-density lipoprotein cholesterol. HR=hazard ratio. LDL-Ccorr=low-density-lipoprotein cholesterol corrected for Lp(a)-536 
cholesterol. SBP=systolic blood pressure. *The group of patients with Lp(a) values <15 mg/dl served as reference group. 537 
  538 
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Figure 1 – Shapes of associations of baseline and on-statin Lp(a) with incident 539 
cardiovascular disease. 540 
 541 
Categories of Lp(a) were defined as <15 mg/dL, 15-<30 mg/dL, 30-<50 mg/dL, and ≥50 mg/dL. Numbers in squared 542 
brackets are means of Lp(a) values within each category. The group with the lowest Lp(a) concentration served as reference. 543 
The analysis of baseline Lp(a) involved 29069 patients (5751 events) in the age- and sex-adjusted model and 27764 patients 544 
(5649 events) in the multivariable adjusted model. Corresponding numbers for the on-statin analysis were 14536 patients 545 
(2603 events) and 13883 patients (2561 events), respectively. *The multivariable model was adjusted for age, sex, prior 546 
cardiovascular disease, diabetes, smoking, systolic blood pressure, low-density-lipoprotein cholesterol corrected for Lp(a)-547 
cholesterol, and high-density lipoprotein cholesterol.  548 
  549 
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Figure 2 – Comparative predictive value of on-statin vs. on-placebo Lp(a) for incident 550 
cardiovascular disease. 551 
 552 
*The multivariable model was adjusted for age, sex, prior cardiovascular disease, diabetes, smoking, systolic blood pressure, 553 
low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol, and high-density lipoprotein cholesterol.  554 
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Figure 3 – Associations of baseline and on-statin Lp(a) with incident cardiovascular disease by individual patient characteristics. 555 
  556 
CI=confidence interval. HDL-C=high-density lipoprotein cholesterol. HR=hazard ratio. LDL-Ccorr=low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol.  557 
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Abstract (300 words) 36 
Background: Elevated lipoprotein(a) [Lp(a)] is a genetic risk factor for cardiovascular 37 
disease (CVD) in general population studies, but its contribution to CVD risk in patients with 38 
established CVD or on statin therapy is uncertain.  39 
Methods: Patient-level data from seven randomized placebo-controlled statin outcomes trials 40 
were collated and harmonized to calculate hazard ratios for CVD, defined as fatal or non-fatal 41 
coronary heart disease, stroke, or revascularisation procedures. Hazard ratios for CVD were 42 
estimated within each trial across pre-defined Lp(a) groups (15-<30, 30-<50, and ≥50 vs. <15 43 
mg/dL), before pooling estimates using multivariate random-effects meta-analysis.  44 
Findings: Analyses included data for 29069 patients with repeat Lp(a) measurements (mean 45 
age 62 years; 28% female; 5751 events during 95576 person-years at risk). Initiation of statin 46 
therapy reduced low-density-lipoprotein cholesterol (mean change [95% CI]:  -3839% [-47 
4443, -3335]) without a significant change in Lp(a). Associations of baseline and on-statin 48 
treatment Lp(a) with CVD risk were approximately linear with increased risk at Lp(a) values 49 
≥30 mg/dL  or  ase ine L (a) and ≥50 mg/dL  or on-statin Lp(a). Age- and sex-adjusted 50 
hazard ratios across Lp(a) groups [referent: Lp(a) <15 mg/dL] were 1·04 (0·91, 1·18), 1·11 51 
(1·00, 1·22), and 1·31 (1·08, 1·58) for baseline Lp(a), and 0·94 (0·81, 1·10), 1·06 (0·94, 52 
1·21), and 1·43 (1·15, 1·76) for on-statin Lp(a). Hazard ratios were virtually identical after 53 
further adjustment for prior CVD, diabetes, smoking, systolic blood pressure, low-density-54 
lipoprotein cholesterol, and high-density-lipoprotein cholesterol. The association of on-statin 55 
Lp(a) with CVD risk was stronger than for on-placebo Lp(a) (interaction P=0·010) and was 56 
more pronounced at younger ages (interaction P=0·008) without effect modification by any 57 
other patient-level or study-level characteristics.  58 
Interpretation: In this individual-patient meta-analysis of statin-treated patients, elevated 59 
baseline and on-statin Lp(a) showed an independent, approximately linear relationship with 60 
CVD risk. This study provides a rationale for testing the Lp(a) lowering hypothesis in CVD 61 
outcomes trials.  62 
Funding: Novartis Pharma AG provided support for the performance of the meta-analysis. 63 
 64 
  65 
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Introduction 66 
Lipoprotein(a) [Lp(a)] is a lipoprotein composed of apolipoprotein(a) covalently bound to 67 
apolipoprotein B (apoB) of a low-density lipoprotein (LDL) like particle.
1,2
 Lp(a) mediates 68 
atherogenicity via its LDL moiety that has a similar proportion of cholesterol content as 69 
traditional LDL particles. In addition, it induces pro-inflammatory responses
3,4
 via 70 
accumulation of oxidised phospholipids
5
 and potentially exerts pro-thrombotic effects via the 71 
plasminogen-like apolipoprotein(a) moiety.
6
 In contrast to other major lipoproteins, there is 72 
no approved specific therapy to lower circulating plasma levels of Lp(a).   73 
Epidemiologic
7
 and genetic
8,9
 evidence has accumulated over the last decade showing that 74 
elevated Lp(a), driven primarily by the LPA gene,
10
 is associated with increased risk of 75 
coronary  heart disease, stroke, peripheral arterial disease, and calcific aortic valve 76 
stenosis.
1,2,11
 These data have established Lp(a) as a cardiovascular disease (CVD) risk factor, 77 
but the bulk of evidence is based on studies involving individuals without prior CVD and 78 
without intensive secondary prevention therapies. In contrast, the role of elevated Lp(a) in 79 
patients with prior CVD events or on statin therapy and other guideline-recommended 80 
therapies is less clear. Prior studies in this patient population yielded inconsistent results, with 81 
findings ranging from significant positive associations to null associations such as following 82 
acute coronary syndromes (reviewed in reference
2
). In addition, several studies, including 83 
JUPITER
12
 and AIM-HIGH
13
, have shown that elevated Lp(a) remain predictive for CVD 84 
risk at LDL-cholesterol (LDL-C) levels <70 mg/dL,
1
 but other studies suggest a positive 85 
association only when LDL-C is elevated.
14
 Furthermore, a major limitation of all post hoc 86 
studies reporting Lp(a) levels and outcomes, is that they involved only a small number of 87 
patients with Lp(a) values above 50 mg/dL and therefore were none recruited patients with 88 
elevated Lp(a) a priori, and therefore the entry Lp(a) levels are usually in the normal range in 89 
70%-80% of study participants. Therefore, all studies thus far have relied on subgroup 90 
analyses and are uniformly underpowered to test the hypothesis that elevated Lp(a) levels in 91 
the setting of statin therapy and prior history of CVD are associated with increased CVD risk 92 
in the setting of statin therapy or prior history of CVD. 93 
To test this hypothesis with adequate statistical power, we established the Lipoprotein(a) 94 
Studies Collaboration, a consortium of patient-level data from placebo-controlled trials of 95 
statins with patient-level data on CVD outcomes and Lp(a) measurements at baseline and 96 
follow-up (i.e. under statin treatment). We now report the results of this analysis in 97 
documenting the associations of baseline and on-treatment Lp(a) with cardiovascular risk.  98 
Methods 99 
Trials included in the meta-analysis 100 
To be eligible in the meta-analysis, randomized placebo-controlled statin trials were required 101 
to have assayed Lp(a) concentration at baseline and follow-up, have recorded incidence of 102 
CVD outcomes using well-defined criteria, and be willing to share patient data at the 103 
individual-level. We included data from AFCAPS, CARDS, 4D, JUPITER, LIPID, 104 
MIRACL, and 4S. Their study design, target population, and entry criteria are summarised in 105 
Table 1; more detailed descriptions of trial designs
15–21
 and Lp(a) methodology and data
12,22–
106 
26
 were previously reported by each trial. Trials not included in the meta-analysis were either 107 
not allowed or willing to provide individual-level patient data. Due to contractual agreements 108 
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on sharing individual patient data, other eligible trials could not be included in the meta-109 
analysis. All contributing trials have obtained ethics approval and  a ien s’ in ormed consent. 110 
Statistical analyses 111 
Analyses were conducted according to a pre-specified analysis plan, developed prior to any 112 
combined analyses. Lp(a) values were loge-transformed. Of 45044 patients enrolled in the 113 
seven trials, 15975 (35·5%) patients were excluded because of missing Lp(a) measurements 114 
at both baseline and follow-up, leaving 29069 patients for analysis (for CONSORT diagram, 115 
please refer to Supplementary Figure 1). ClinicalThere were minimal differences in 116 
baseline characteristics of patients with or without available Lp(a) measurements excluded 117 
were similar to those of patients included in the analysis (Supplementary Table 1). In all 118 
trials except 4S, on-statin Lp(a) during follow-up was measured at one time-point. In the 4S 119 
trial, on-statin Lp(a) was estimated as the geometric mean of Lp(a) values assessed at up to 120 
four distinct time points. Lp(a) values provided in nmol/L were divided by 2·4 (JUPITER), as 121 
previously described
27
, and those provided in IU/L by 19·07 (4S) to convert them to the 122 
common unit of mg/dL. When information on Lp(a) was missing either at baseline (0·5%) or 123 
at follow-up (5·5%), their Lp(a) value was mean-imputed from study-specific mixed-effects 124 
models which predicted Lp(a) values using fixed effects for assigned treatment, time-in-125 
study, and the interaction of the two variables, plus a random intercept allowed to vary at the 126 
patient levelincluded fixed effects of Lp(a) values available for that patient at other time 127 
points, the time between repeat measurements, and trial arm, plus random effects at the 128 
patient level.  129 
Because  on en iona  “L L- ” assa s  a   re  ho es ero  both in LDL and Lp(a) particles, 130 
LDL-C values were corrected for the latter. Lp(a) mass in mg/dL is composed of ~30-45% 131 
cholesterol.
28
 We used a conservative measurement of the content of Lp(a)-C by multiplying 132 
Lp(a) mass (in mg/dL) by 0·30 to derive Lp(a)-cholesterol, and then subtracting this value 133 
from the measured LDL-C to obtain corrected LDL-C (LDL-Ccorr).
28
  134 
The combined CVD endpoint was defined as the occurrence of fatal or non-fatal coronary 135 
heart disease, stroke, or any coronary or carotid revascularisation procedures. In analysing 136 
on-treatment Lp(a), all CVD events that occurred after randomisation were considered 137 
because any change in Lp(a) under statin therapy is anticipated to occur within a short time 138 
period (sensitivity analyses omitted the initial period of follow-up).
12
  139 
Associations of Lp(a) with CVD risk were estimated using a two-step approach, with 140 
estimates calculated within each study separately before pooling them across studies using 141 
multivariate random-effects meta-analysis.
29
 The analysis of baseline Lp(a) involved all 142 
patients, whereas the analysis of on-treatment Lp(a) was restricted to patients assigned to the 143 
intervention arm. Hazard ratios were calculated using Cox proportional hazard regression 144 
models which used time-on-study as a timescale, were stratified by trial arm, and compared 145 
the pre-specified Lp(a) groups <15 mg/dL, 15-<30 mg/dL, 30-<50 mg/dL  and ≥50 mg/dL. 146 
The assumptions for the proportionality of hazards was tested using Schoenfeld residuals and 147 
were was met. The analysis had four inter-related principal aims. First, to evaluate shapes of 148 
associations, pooled hazard ratios were calculated over Lp(a) groups and plotted against the 149 
pooled geometric mean of Lp(a) concentration within each category.
29
 Second, to determine 150 
the extent of confounding, hazard ratios were progressively adjusted for age, sex, prior CVD, 151 
diabetes, smoking, systolic blood pressure, LDL-Ccorr, and high-density-lipoprotein-152 
cholesterol (“m   i aria  e adjusted mode ”). Further adjustment for body-mass index and 153 
estimated glomerular filtration rate was employed in the subset of patients, in which these 154 
data were available. Third, to investigate whether the predictive value of follow-up Lp(a) 155 
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differed between patients randomized to statin vs. placebo, interaction models by trial arm 156 
were fitted. Fourth, to investigate effect modification by individual-patient and study-level 157 
characteristics, formal tests of interaction and meta-regression analyses with these variables 158 
were performed. There was little variability within each trial of the proportion of patients 159 
with prior CVD and with a history of diabetes at baseline (e.g. secondary vs. primary CVD 160 
prevention trials, diabetes as inclusion or exclusion criterion) and hence effect modification 161 
by these characteristics was investigated at the study-level instead of at the patient-level. 162 
Between-trial heterogeneity was assessed with the I
2
 statistic.
30
 Analyses were performed 163 
using Stata (version 14·1 MP) and involved two-sided statistical tests and 95% confidence 164 
intervals. Principal analyses used a significance level of P<0·05 and subgroup analyses a 165 
Bonferroni-corrected significance level of P<0·007 (for seven subgroups). 166 
Role of funding source 167 
The funders of the study had no role in study design, data collection, data analysis, data 168 
interpretation, or writing of the report. PW and ST had full access to all the data in the study 169 
and had final responsibility for the decision to submit for publication.  170 
Results 171 
Summary of available data 172 
Data on 29069 patients from seven contributing trials were analysed (Table 2). At trial entry, 173 
mean age was 62 years (SD 8), 806428% were female (28%), 1525252% had prior CVD 174 
(52%), 517718% had diabetes (18%), 484717% were current smokers (17%), mean systolic 175 
blood pressure was 137 mmHg (SD 18), and mean LDL-Ccorr was 3·30 mmol/L (SD 0·67). 176 
Median concentration of Lp(a) at baseline was in low normal range of 11 mg/dL 177 
(interquartile range: 5-29). In cross-sectional analyses, baseline Lp(a) concentration was 178 
higher in females (+12% [3, 21]), lower in patients with diabetes (-17% [-24, -9]) and 179 
unrelated to smoking (+2% [-3, 8]). Furthermore, LDL-Ccorr, loge triglycerides, body-mass 180 
index, and systolic blood pressure were associated with a lower and HDL-C with a higher 181 
Lp(a) concentration (age-and sex-adjusted differences in Lp(a) per SD: -16% [-23, -8], -12% 182 
[-15, -9], -7% [-10, -5], -2% [-5, -0], and +7% [3, 11]). Baseline Lp(a) was not associated 183 
with age (-1% [-2, 1] per SD).  184 
A total of 14,536 patients were randomized to receive statin therapy (Table 2). Initiation of 185 
statin therapy reduced LDL-Ccorr by -3839% (95% confidence interval: -4443, -3335). The 186 
effect of statin on Lp(a) concentration was heterogeneous across trials; the pooled percentage 187 
change was -0·4% (-7, 7), with three trials showing a mean increase (range +2 to +15%) and 188 
four trials showing a mean decrease (range -1 to -13%) in Lp(a). The median concentration of 189 
Lp(a) on statin therapy was 11 mg/dL (interquartile range: 5-32). The age- and sex-adjusted 190 
correlation between baseline and follow-up loge Lp(a) was comparable in the statin arm and 191 
the placebo arm (r=0.948 vs. 0.952). 192 
Associations of baseline and on-statin Lp(a) with cardiovascular disease risk 193 
During 95576 person-years at risk (median follow-up 3·0 years [interquartile range: 1·5-194 
5·3]), a total of 5751 CVD events were recorded, of which 2603 occurred in the statin arm 195 
(Table 2). When patients were grouped by Lp(a) concentration into the categories <15 196 
mg/dL, 15-<30 mg/dL, 30-<50 mg/dL  and ≥50 mg/dL  in idence rates for CVD (95% CI) 197 
per 1000 person-years were as follows: 55·3 (53·4-57·3), 56·3 (52·6-60·2), 66·7 (62·0-71·8), 198 
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and 80·0 (75·3-84·9) for baseline Lp(a), and 49·0 (46·5-51·6), 46·4 (41·6-51·7), 56·2 (50·3-199 
62·8), and 77·2 (71·1-83·8) for on-statin Lp(a). 200 
In analyses adjusted for age and sex only, associations of baseline and on-statin Lp(a) values 201 
with the risk of CVD were of positive approximately linear shape, with a possible threshold 202 
effect in the group with Lp(a) values of 50 mg/dL or more (Figure 1). For baseline Lp(a), the 203 
hazard ratios compared to patients with Lp(a) values of <15 mg/dL were 1·04 (0·91, 1·18) 204 
with Lp(a) values 15-<30 mg/dL, 1·11 (1·00, 1·22) with Lp(a) values 30-<50 mg/dL, and 205 
1·31 (1·08, 1·58) with Lp(a) values ≥50 mg/dL (Table 3). For on-statin Lp(a), corresponding 206 
hazard ratios were 0·94 (0·81, 1·10), 1·06 (0·94, 1·21), and 1·43 (1·15, 1·76).  207 
Associations were remained robust to additional multivariable adjustment for age, sex, prior 208 
CVD, diabetes, smoking, systolic blood pressure, LDL-Ccorr, and HDL-C concentration 209 
(Figure 1 and Table 3). Corresponding hazard ratios were 1·04 (0·91, 1·20), 1·13 (1·02, 210 
1·25), and 1·35 (1·11, 1·66) for baseline Lp(a) and 0·95 (0·82, 1·11), 1·08 (0·95, 1·23), and 211 
1·42 (1·16, 1·74) for on-statin Lp(a). In a sensitivity analysis of patients with information on 212 
triglycerides, body-mass index, or estimated glomerular filtration rate, further adjustment for 213 
these parameters did not materially change the magnitude of association between Lp(a) 214 
measurements and CVD risk (Supplementary Table 2). Effect sizes comparable with those 215 
in the principal analysis were observed when further categorising the highest Lp(a) group into 216 
patients with levels 50-<75 mg/dL and ≥75 mg/dL (Supplementary Table 3) and in the on-217 
statin analysis when omitting events that occurred in the initial period between randomization 218 
and on-statin measurement of Lp(a) (Supplementary Table 4). Trial-specific findings are 219 
provided in Supplementary Table 5. 220 
Comparative predictive value of on-statin vs. on-placebo Lp(a) 221 
Lp(a) concentration measured during follow-up was more strongly associated with CVD risk 222 
in the on-statin arm than in the on-placebo arm (Figure 2). In comparison of patients with 223 
Lp(a) ≥50 mg/dL with those having Lp(a) <50 mg/dL, the age- and sex-adjusted hazard ratios 224 
for CVD were 1·48 (1·23 to 1·78) for on-statin Lp(a) and 1·23 (1·04 to 1·45) for on-placebo 225 
Lp(a) (interaction P=0·010). The corresponding multivariable adjusted hazard ratios were 226 
1·47 (1·25 to 1·73) and 1·26 (1·06 to 1·50) (interaction P=0·031). The median time from 227 
randomization to Lp(a) repeat was 1.0 years in both trial arms. 228 
Associations according to patient-level and study-level characteristics 229 
There was some heterogeneity between trials in hazard ratios for CVD, most pronounced in 230 
the group with a Lp(a) concentrations ≥50 mg/dL. For example, in this group, I2 values of 231 
age- and sex-adjusted hazard ratios were 73% (43, 88) for baseline Lp(a) and 62% (13, 83) 232 
for on-statin Lp(a) (Table 3). Apart from stronger associations of on-statin Lp(a) with CVD 233 
risk at younger age (<60 years vs. 60-<70 years vs. ≥70 years; interaction P=0·008), hazard 234 
ratios did not vary significantly across clinically relevant subgroups, such as by sex, smoking, 235 
systolic blood pressure, lipid parameters, or body-mass index (Figure 3). Furthermore, the 236 
magni  de o  asso ia ion was inde enden  o  a s  d ’s  ro or ion o   a ien s wi h  rior  V  237 
or diabetes, the length of follow-up for clinical events, and the time between study baseline 238 
and follow-up on-statin Lp(a) measurement (Supplementary Figure 2). Contributing trials 239 
employed differing statin interventions, precluding a subgroup analysis by statin type or 240 
statin dosage.  241 
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Discussion 242 
This well-powered meta-analysis of Lp(a) and CVD events reveals that patients with elevated 243 
Lp(a) on statin therapy, primarily with levels of >50 mg/dL, are at a significantly higher risk 244 
of CVD. The association with CVD risk was independent of conventional CVD risk factors, 245 
as also reflected in the very weak or null cross-sectional correlations of Lp(a) with these risk 246 
factors. Importantly, hazard ratios for high Lp(a) at baseline and under statin therapy were of 247 
similar magnitude, reflecting that statin therapy may not appreciably affect Lp(a)-mediated 248 
risk in patients with elevated Lp(a). Overall, these data suggest that patients with elevated 249 
Lp(a), representing ~25% of subjects with prior CVD or statin indication,
1
 are at substantial 250 
residual risk even under statin therapy. In this patient population, therapies which specifically 251 
lower Lp(a) might mitigate Lp(a)-mediated risk. An appropriately designed CVD outcomes 252 
trial with robust Lp(a)-lowering is therefore justified to test the hypothesis that lowering 253 
Lp(a) reduces CVD events, independent of statin treatment.  254 
At baseline, Lp(a) levels were weakly associated with demographic and laboratory variables. 255 
The most significant but nevertheless weak correlations were inverse with diabetes mellitus 256 
and triglycerides. The observation of an inverse association of Lp(a) with incident diabetes 257 
has been made previously,
31
 and is most pronounced at very low levels of Lp(a) (5 mg/dL), 258 
which are present in the 10th percentile of the global population.
1,2
 It has not been determined 259 
if the findings are causal or if there is confounding by reverse causality.
32
 Although the 260 
underlying mechanisms are not well understood, fasting and post-prandial insulin levels are 261 
inversely associated with Lp(a).
33
 Lp(a) was weakly correlated with LDL-C, but this 262 
relationship became inversely associated after subtracting the estimated cholesterol content in 263 
Lp(a) from the laboratory measurement called “L L- ”.28  264 
Prior studies evaluating the role of Lp(a) in predicting CVD in patients without CVD, using 265 
Lp(a) assays in the modern era that lack limitations of prior assays, have been almost 266 
uniformly positive.
7
 However, studies in patients with prior CVD or on statin therapy have 267 
been mixed, or have suggested the effect is present primarily in patients with elevated LDL-C 268 
(reviewed in Tsimikas et al.
2
). A major limitation of all substudies reporting Lp(a) and 269 
outcomes has been power. All studies have enrolled patients with Lp(a) levels in the mid to 270 
low normal range (10-15 mg/dL, normal <30 mg/dL), as confirmed in the current meta-271 
analysis, thus statistical power to evaluate risk in patients with highly elevated Lp(a) (i.e. >50 272 
mg/dL) was limited. The current study is highly powered with 5751 total events and 2603 273 
events in the statin arms, making it equivalent to, or larger than, most individual randomised 274 
controlled cardiovascular outcome trials in the modern era. In contrast to a previous analysis 275 
of individual- a ien  da a    O’ onogh e e  a  34 our study afforded higher statistical power 276 
because it involved >10 times more CVD events, and hence was able to characterise 277 
associations with high Lp(a) concentrations more precisely. Moreover, the present analysis 278 
used clinically-relevant Lp(a) categories informed by guideline recommendations, as opposed 279 
to trial-specific quintiles. 280 
The current meta-analysis is also highly representative of clinical care in patients treated with 281 
statins. First, these studies represent patients that who were treated with moderate-high doses 282 
of the five major statins used clinically. Second, they reflect the variety of patients treated 283 
clinically, including primary prevention, high-risk primary prevention with elevated C-284 
reactive protein or diabetes, secondary prevention, stable coronary artery disease, diabetes, 285 
acute coronary syndromes, patients on dialysis and highly elevated LDL-C in the familial 286 
hypercholesterolemia range. Therefore, they broadly reflect the patients with high residual 287 
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risk despite statin treatment, potentially due to other, unmodified risk factors such as elevated 288 
Lp(a)at risk for Lp(a)-mediated CVD. 289 
The risk thresholds chosen reflect clinical risk as suggested by epidemiologic and genetic 290 
studies. The reference cutoff of <15 mg/dL, reflects roughly the median global level of 291 
Lp(a).
35,36
 Lp(a) <30 mg/dL represents the usual cutoff in US laboratories that is considered 292 
as normal level, and is based on data showing that risk of myocardial infarction starts to 293 
accrue at levels above 25-30 mg/dL.
7,37
 The range of 30-50 mg/dL was chosen as this is the 294 
grey zone between what is considered pathophysiologically relevant and >50 mg/dL is based 295 
on what the European Atherosclerosis Society as considered elevated levels at highest risk 296 
based on the European population prevalence of 20%.  297 
In this study, elevation of CVD risk became evident at baseline Lp(a) 30 to <50 mg/dL and 298 
was further pronounced when Lp(a) levels exceeded 50 mg/dL, including patients treated 299 
with statins. The hazard ratios for Lp(a) ≥50 mg/dL are consistent with recent PCSK9 300 
inhibitor studies in patients with background statin therapy.
38
 Additional analyses at even 301 
higher Lp(a), i.e. ≥75 mg/dL were limited by low power due to small numbers of patients 302 
with Lp(a) levels in this range, but support a graded relationship of Lp(a) with cardiovascular 303 
risk. Outcome trials of Lp(a) lowering are likely to include patients with mean baseline Lp(a) 304 
substantially >50 mg/dL, therefore, extrapolation to event reduction with Lp(a) lowering 305 
from these data may be an underestimate. 306 
A key observation of this study is that on-statin Lp(a) was more strongly associated with 307 
CVD risk than on-placebo Lp(a).  A small angiographic study initially suggested that the risk 308 
of Lp(a) is attenuated when LDL-C is well controlled.
39
 In contrast, the current study, 309 
utilising a far larger body of data, supports the opposite conclusion that risk is independently 310 
associated with both LDL-C and Lp(a). When LDL-attributable risk is reduced with statin 311 
treatment, Lp(a)-associated risk becomes an even stronger predictor of residual risk. This 312 
observation is particularly evident at Lp(a) levels exceeding 50 mg/dL. In support of our 313 
observation in this study, the trials FOURIER (European Atherosclerosis Society, May 2018) 314 
and ODYSSEY OUTCOMES (International Atherosclerosis Society, June 2018) have 315 
recently presented preliminary findings of their data, both showing that elevated baseline 316 
Lp(a) remains a risk factor even with on-treatment LDL-C <50 mg/dL in patients treated with 317 
statins and PCSK9 inhibitors. The findings raise the importance of determining whether there 318 
is a cardiovascular benefit of treatment to reduce Lp(a) when initial levels exceed this 319 
threshold, irrespective of concurrent treatment with statin. A second important observation is 320 
that all major subgroups of patients seemed to be at risk of elevated Lp(a), including those 321 
>70 years old, females, smokers, those with low and high LDL-Ccorr, low HDL-C and all 322 
categories of body-mass index. The current study suggests that the relationship of Lp(a) to 323 
risk is curvilinear if plotted on a geometric mean scale, but linear if plotted on continuous 324 
scale, suggesting that potent reduction in Lp(a) may be clinically beneficial across all 325 
elevated Lp(a) levels.  326 
It is important to emphasize that the Lp(a) hypothesis remains to be tested. To do so requires 327 
a randomized trial that compares cardiovascular outcomes in patients treated with an agent 328 
that specifically lowers Lp(a) versus placebo. Such a trial may be possible with antisense 329 
oligonucleotide targeting LPA messenger RNA, thereby reducing plasma Lp(a) levels. Phase 330 
I and II trials with this agent have shown the potential to lower Lp(a) levels by over 90% 331 
without major effects on other classes of lipoproteins.
27,40
  332 
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One limitation of this study is that individual-patient data could not be obtained from several 333 
other statin trials that reported Lp(a) levels and outcomes. It is possible that inclusion of other 334 
data would have modified the observed effect sizes. Secondly, the relationship of Lp(a) to 335 
residual cardiovascular risk under treatment with non-statin lipid-modifying agents (e.g., 336 
ezetimibe, PCSK9 inhibitors) remains undetermined. Third, the Lp(a) assays were 337 
heterogeneous and most were in Lp(a) mass rather than in Lp(a) molar concentration and the 338 
timepoints at which they were measured in each trial were not uniform. Therefore, the assays 339 
not reported in mg/dL had to be mathematically converted to mg/dL, which may have 340 
introduced imprecision into introduce bias into the Lp(a) measurement precision. A recent 341 
NHLBI Working Group on Lp(a) recommended global standardization of Lp(a) assays to 342 
address this limitation.
2
 Fourth, we cannot rule out that index event bias may have attenuated 343 
effect sizes in secondary prevention trials, although the scope of this bias was reduced by 344 
employment of multivariable adjustment. Fifth, our analysis identified moderate to high 345 
between-study heterogeneity, which could not be explained by baseline disease status (i.e. 346 
prior CVD or prior diabetes) nor by differing lengths of follow-up periods. Finally, the data 347 
for the change in Lp(a) post statin therapy was heterogeneous across studies, with both 348 
increases and decreases, but no net change. Due to different assays used in each of the trials, 349 
and the need for conversion of all data to mg/dL, and the hihgerhigher precision required to 350 
show intra-individual changes, these data should be considered hypothesis generating. A 351 
more robust test of this particular hypothesis should ideally be performed using the same 352 
assay. 353 
In conclusion, this meta-analysis demonstrates an approximately linear relationship of 354 
cardiovascular risk to levels of Lp(a), evident at Lp(a) levels 30-50 mg/dL, pronounced at 355 
levels ≥50 mg/dL, and persisting despite statin treatment. These data provide a rationale for 356 
evaluating drugs that can specifically lower Lp(a) and might have the potential to reduce 357 
residual cardiovascular risk independent of statin treatment. 358 
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Research in context  517 
Evidence before this study:  Lp(a) has been associated with increased risk of incident 518 
cardiovascular disease in primary care populations, but its role in predicting cardiovascular 519 
events in the risk of high-risk patients in the setting of statin therapy is not known treated 520 
with statins is unclear. We searched PubMed for relevant clinical trials published up to July 521 
9, 2018, using the search terms "Lipoprotein(a)" or "Lp(a)", plus “statin” and "cardiovascular 522 
diseases"[MeSH]. Our review identified seven statin trials (4D, 4S, FLARE, JUPITER, 523 
LIPID, MIRACL, and TNT), which reported on the association of Lp(a) with cardiovascular 524 
risk. The interpretation of the available evidence is complicated by inconsistent findings 525 
across trials (positive vs. null associations), limited statistical power of single trials, limited 526 
availability of follow-up Lp(a) measurements, and differing definitions of Lp(a) categories 527 
across trials. 528 
Added value of this study:  We obtained patient-level data in seven placebo-controlled 529 
statin trials encompassing 29069 patients and analysed the relationship of baseline and on-530 
treatment Lp(a)  in the setting of statin therapyto risk of major adverse cardiovascular events. 531 
Elevated Lp(a) of 50 mg/dL or higher, at baseline or on-treatment, was associated with an 532 
increased hazard ratio of cardiovascular disease events independent of other cardiovascular 533 
risk factors and evident on treatment with either statin or placebo.  534 
Implications of all the available evidence:  These data suggest that residual risk in is 535 
present in patients with elevated Lp(a) that is not addressed by statins and supports the 536 
rationale for outcomes trials to test specific therapies to lower Lp(a). 537 
  538 
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Tables 539 
 540 
Table 1 – Design features of contributing trials. 541 
Cohort 
Years of 
baseline 
Target population Lipid entry criteria, mmol/L 
Comparator to 
placebo 
CVD outcome 
definition 
M
I 
S
ta
b
le
 a
n
g
in
a
 
S
tr
o
k
e 
R
ev
a
sc
u
la
ri
sa
ti
o
n
 
O
th
er
 
AFCAPS15 1990-1993 Primary prevention TC 4·.65-6·.82, LDL-C 3·.36-
4·.9   TG ≤4·.52, HDL-C 
≤ ·. 6♂ and ≤ ·.22♀ 
Lovastatin 20mg ● ● ● ● ●* 
CARDS22 1997-2001 Type 2 diabetes LDL-  ≤4·. 4  TG ≤6·.78 Atorvastatin 10mg ● ○ ● ● ○ 
4D23 1998-2002 Type 2 diabetes + 
hemodialysis 
LDL-C 2·.07-4·.92  TG ≤  ·.3 Atorvastatin 20mg ● ○ ● ● ○ 
JUPITER12 2003-2006 Primary prevention 
with C-reactive 
protein >2mg/dL 
LDL-C <3·.4, TG <5·.65 Rosuvastatin 20mg ● ○ ● ● ●† 
LIPID24 1990-1992 Prior myocardial 
infarction or unstable 
angina 
TC 4·.0-7·.0, TG <5·.0 Pravastatin 40mg ● ○ ● ● ○ 
MIRACL25 1997-1999 Acute coronary 
syndrome 
TC <7·.0 Atorvastatin 80mg ● ○ ● ● ○ 
4S26 1989-1990 Prior myocardial 
infarction or angina 
TC 5·.5-8·.0  TG ≤2·.5 Simvastatin 20mg ● ○ ○ ● ○ 
AFCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study. CARDS=Collaborative Atorvastatin Diabetes 542 
Study. CVD=cardiovascular disease. 4D=Die Deutsche Diabetes-Dialyse-Studie. HDL-C=high-density lipoprotein 543 
cholesterol. JUPITER=Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin. 544 
LDL-C=low-density lipoprotein cholesterol. LIPID=Long-Term Intervention with Pravastatin in Ischaemic Disease. 545 
MI=myocardial infarction. MIRACL=Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. 546 
4S=Scandinavian Simvastatin Survival Study. TC=total cholesterol. TG=triglycerides. *Transient ischemic attack, peripheral 547 
vascular disease, sudden death, and deaths from other cardiovascular causes. †Deaths from other cardiovascular causes. 548 
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Table 2 – Patient characteristics. 550 
  AFCAPS CARDS 4D JUPITER LIPID MIRACL 4S Total 
Baseline   
      
No. of patients 1005 2470 1249 9612 7863 2431 4439 29069 
Lp(a), mg/dL, median (IQR) 7 (3-17) 9 (5-22) 12 (5-42) 11 (5-23) 14 (7-44) 10 (5-29) 10 (4-28) 11 (5-29) 
<15 mg/dL 733 (73) 1658 (67) 709 (57) 5896 (61) 4118 (52) 1481 (61) 2654 (60) 17249 (59) 
15-<30 mg/dL 134 (13) 310 (13) 129 (10) 1867 (19) 1147 (15) 362 (15) 781 (18) 4730 (16) 
30-<50 mg/dL 84 (8) 212 (9) 140 (11) 851 (9) 877 (11) 223 (9) 714 (16) 3101 (11) 
≥50 mg/dL 54 (5) 290 (12) 271 (22) 998 (10) 1721 (22) 365 (15) 290 (7) 3989 (14) 
Age, yrs 59 (7) 62 (8) 66 (8) 66 (8) 61 (8) 65 (11) 59 (7) 62 (8) 
Female sex 173 (17) 779 (32) 576 (46) 3556 (37) 1333 (17) 820 (34) 827 (19) 8064 (28) 
Prior CVD 0 (0) 6 (0) 513 (41) 0 (0) 7863 (100) 2431 (100) 4439 (100) 15252 (52) 
Diabetes 32 (3) 2470 (100) 1249 (100) 0 (0) 676 (9) 548 (23) 202 (5) 5177 (18) 
Current smoking 130 (13) 551 (22) 108 (9) 1492 (16) 735 (9) 693 (29) 1138 (26) 4847 (17) 
SBP, mmHg 136 (17) 144 (16) 146 (22) 136 (17) 134 (19) 128 (20) 139 (20) 137 (18) 
LDL-Ccorr, mmol/L – 2.·75 (0.·78) 3.·00 (0.·86) 2.·57 (0.·49) 3.·68 (0.·74) 3.·04 (0.·86) 4.·74 (0.·66) 3.·30 (0.·67) 
HDL-C, mmol/L – 1.·64 (0.·50) 0.·94 (0.·34) 1.·35 (0.·40) 0.·96 (0.·24) 1.·20 (0.·31) 1.·19 (0.·30) 1.·21 (0.·35) 
BMI, kg/m² 26 (3) 29 (4) 28 (5) 29 (6) – 28 (5) 26 (3) 28 (5) 
eGFR, mL/min – – – 75 (17) 71 (17) – – 73 (17) 
Apo-B, g/L – 1.·16 (0.·24) 1.·10 (0.·30) 1.·08 (0.·21) 1.·33 (0.·25) – 1.·16 (0.·18) 1.·17 (0.·23) 
On-statin 
        
No. of patients 504 1255 616 4802 3941 1200 2218 14536 
Time to Lp(a) repeat, yrs, median 1.·0 2.·5 0.·5 1.·0 1.·0 0.·2 2.·5 1.·0 
Lp(a), mg/dL, median (IQR) 7 (3-19) 8 (4-22) 11 (5-40) 11 (4-25) 13 (6-43) 11 (5-33) 11 (4-33) 11 (5-32) 
<15 mg/dL 366 (73) 864 (69) 351 (57) 2912 (61) 2106 (53) 707 (59) 1268 (57) 8574 (59) 
15-<30 mg/dL 59 (12) 134 (11) 60 (10) 868 (18) 548 (14) 175 (15) 321 (15) 2165 (15) 
30-<50 mg/dL 43 (9) 103 (8) 73 (12) 417 (9) 439 (11) 96 (8) 375 (17) 1546 (11) 
≥50 mg/dL 36 (7) 154 (12) 132 (21) 605 (13) 848 (22) 222 (19) 254 (12) 2251 (15) 
% change vs. baseline (95% CI) -1% (-6, 4) -13% (-15, -10) -6% (-9, -3) 2% (1, 3) -7% (-8, -5) 9% (6, 12) 15% (13, 17) -0.·4% (-7, 7) 
LDL-Ccorr, mmol/L – 1.·68 (0.·58) 1.·73 (0.·78) 1·43 (0·70) – 2.·57 (0.·71) 1.·56 (0.·77) 2.·97 (0.·70) 1.·99 (0.·70) 
% change vs. baseline (95% CI) – -37% (-38, -36) -41% (-43, -39) -43% (-44, -
42)– 
-29% (-30, -29) -47% (-49, -46) -37% (-37, -36) -389% (-443, -
335) CVD incidence 
        
Follow-up, yrs, median (IQR) 5·.6 (4·.8-6·.2) 4·.1 (3·.1-4·.8) 2·.4 (1·.4-3·.7) 2·.0 (1.·5-2.·4) 5.·4 (3.·1-6.·0) 0.·3 (0.·3-0.·3) 5.·3 (3.·9-5.·5) 3.·0 (1.·5-5.·3) 
No. of events, overall 68 170 338 234 3040 537 1364 5751 
No. of events, statin arm 31 71 166 81 1428 258 568 2603 
Mean (SD) or n (%), unless stated otherwise. Percentages may not sum up to 100% due to rounding. For full trial names, refer to footnote of Table 1. Total means (standard 551 
deviations) and % changes (95% confidence intervals) were calculated by pooling study-specific estimates with random-effects meta-analysis. Apo-B=apolipoprotein B. 552 
BMI=body-mass index. CVD=cardiovascular disease. eGFR=estimated glomerular filtration rate. HDL-C=high-density lipoprotein cholesterol. IQR=interquartile-range. LDL-553 
Ccorr=low-density lipoprotein cholesterol corrected for Lp(a)-cholesterol. SBP=systolic blood pressure.  554 
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Table 3 – Associations of baseline and on-statin Lp(a) with incident cardiovascular disease according to different levels of adjustment. 555 
Lp(a) measurement / 
adjustment 
Lp(a) 15-<30 mg/dL 
 
Lp(a) 30-<50 mg/dL 
 
Lp(a) ≥50 mg/dL 
 
HR (95% CI)* P value I2 (95% CI)  HR (95% CI)* P value I2 (95% CI)  HR (95% CI)* P value I2 (95% CI) 
Baseline Lp(a) 
Basic adjustment: 7 trials – 29069 patients – 5751 events  
Age- and sex-adjusted 
1.·04 (0.·91, 
1.·18) 
0.·594 43% (0, 76) 
 1.·11 (1.·00, 
1.·22) 
0.·047 0% (0, 71) 
 1.·31 (1.·08, 
1.·58) 
0.·005 73% (43, 88) 
Progressive adjustment: 6 trials – 27764 patients – 5649 events  
Age- and sex-adjusted 
1.·03 (0.·90, 
1.·18) 
0.·642 54% (0, 81) 
 1.·10 (1.·00, 
1.·22) 
0.·053 0% (0, 75) 
 1.·30 (1.·06, 
1.·59) 
0.·010 78% (52, 90) 
  Plus prior CVD 
1.·04 (0.·90, 
1.·19) 
0.·6071 53% (0, 81) 
 1.·10 (1.·00, 
1.·22) 
0.·049 0% (0, 75) 
 1.·31 (1.·07, 
1.·60) 
0.·009 78% (52, 90) 
  Plus diabetes 
1.·04 (0.·91, 
1.·19) 
0.·604 52% (0, 81) 
 1.·11 (1.·01, 
1.·23) 
0.·036 0% (0, 75) 
 1.·32 (1.·08, 
1.·61) 
0.·007 78% (51, 90) 
  Plus smoking 
1.·03 (0.·91, 
1.·18) 
0.·613 50% (0, 80) 
 1.·11 (1.·01, 
1.·22) 
0.·034 0% (0, 75) 
 1.·31 (1.·08, 
1.·59) 
0.·007 77% (48, 90) 
  Plus SBP 
1.·03 (0.·90, 
1.·18) 
0.·6364 53% (0, 81) 
 1.·11 (1.·01, 
1.·22) 
0.·031 0% (0, 75) 
 1.·31 (1.·07, 
1.·59) 
0.·008 77% (49, 90) 
  Plus LDL-Ccorr 
1.·04 (0.·90, 
1.·19) 
0.·6071 55% (0, 82) 
 1.·12 (1.·02, 
1.·24) 
0.·019 0% (0, 75) 
 1.·34 (1.·09, 
1.·65) 
0.·005 78% (53, 90) 
  Plus HDL-C 
1.·04 (0.·91, 
1.·20) 
0.·543 54% (0, 82) 
 1.·13 (1.·02, 
1.·25) 
0.·016 0% (0, 75) 
 1.·35 (1.·11, 
1.·66) 
0.·003 77% (49, 90) 
On-statin Lp(a) 
Basic adjustment: 7 trials – 14536 patients – 2603 events  
Age- and sex-adjusted 
0.·94 (0.·81, 
1.·10) 
0.·451 18% (0, 62) 
 1.·06 (0.·94, 
1.·21) 
0.·332 0% (0, 71) 
 1.·43 (1.·15, 
1.·76) 
0.·001 62% (13, 83) 
Progressive adjustment: 6 trials – 13883 patients – 2561 events  
Age- and sex-adjusted 
0.·93 (0.·79, 
1.·09) 
0.·3667 18% (0, 63) 
 1.·06 (0.·93, 
1.·21) 
0.·351 0% (0, 75) 
 1.·39 (1.·12, 
1.·72) 
0.·002 64% (13, 85) 
  Plus prior CVD 
0.·93 (0.·79, 
1.·09) 
0.·3667 18% (0, 63) 
 1.·06 (0.·93, 
1.·21) 
0.·3596 0% (0, 75) 
 1.·39 (1.·12, 
1.·72) 
0.·002 64% (13, 85) 
  Plus diabetes 
0.·94 (0.·80, 
1.·10) 
0.·431 17% (0, 62) 
 1.·07 (0.·94, 
1.·22) 
0.·3071 0% (0, 75) 
 1.·39 (1.·13, 
1.·71) 
0.·002 62% (7, 84) 
  Plus smoking 
0.·94 (0.·81, 
1.·09) 
0.·4152 8% (0, 77) 
 1.·07 (0.·94, 
1.·22) 
0.·30297 0% (0, 75) 
 1.·39 (1.·13, 
1.·71) 
0.·002 62% (8, 84) 
  Plus SBP 
0.·94 (0.·81, 
1.·09) 
0.·412 9% (0, 77) 
 1.·07 (0.·94, 
1.·22) 
0.·30299 0% (0, 75) 
 1.·39 (1.·13, 
1.·71) 
0.·002 61% (6, 84) 
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  Plus LDL-Ccorr 
0.·94 (0.·81, 
1.·10) 
0.·4657 13% (0, 78) 
 1.·08 (0.·95, 
1.·23) 
0.·2556 0% (0, 75) 
 1.·41 (1.·15, 
1.·73) 
0.·001 61% (3, 84) 
  Plus HDL-C 
0.·95 (0.·82, 
1.·11) 
0.·5273 13% (0, 78) 
 1.·08 (0.·95, 
1.·23) 
0.·240 0% (0, 75) 
 1.·42 (1.·16, 
1.·74) 
0.·001 58% (0, 83) 
CI=confidence interval. CVD=cardiovascular disease. HDL-C=high-density lipoprotein cholesterol. HR=hazard ratio. LDL-Ccorr=low-density-lipoprotein cholesterol corrected for Lp(a)-556 
cholesterol. SBP=systolic blood pressure. *The group of patients with Lp(a) values <15 mg/dl served as reference group. 557 
  558 
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Figure 1 – Shapes of associations of baseline and on-statin Lp(a) with incident 559 
cardiovascular disease. 560 
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 562 
Categories of Lp(a) were defined as <15 mg/dL, 15-<30 mg/dL, 30-<50 mg/dL  and ≥50 mg/dL. Numbers in squared 563 
brackets are means of Lp(a) values within each category. The group with the lowest Lp(a) concentration served as reference. 564 
The analysis of baseline Lp(a) involved 29069 patients (5751 events) in the age- and sex-adjusted model and 27764 patients 565 
(5649 events) in the multivariable adjusted model. Corresponding numbers for the on-statin analysis were 14536 patients 566 
(2603 events) and 13883 patients (2561 events), respectively. *The multivariable model was adjusted for age, sex, prior 567 
cardiovascular disease, diabetes, smoking, systolic blood pressure, low-density-lipoprotein cholesterol corrected for Lp(a)-568 
cholesterol, and high-density lipoprotein cholesterol.  569 
  570 
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Figure 2 – Comparative predictive value of on-statin vs. on-placebo Lp(a) for incident 571 
cardiovascular disease. 572 
573 
 574 
*The multivariable model was adjusted for age, sex, prior cardiovascular disease, diabetes, smoking, systolic blood pressure, 575 
low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol, and high-density lipoprotein cholesterol.  576 
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Figure 3 – Associations of baseline and on-statin Lp(a) with incident cardiovascular disease by individual patient characteristics. 577 
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 579 
CI=confidence interval. HDL-C=high-density lipoprotein cholesterol. HR=hazard ratio. LDL-Ccorr=low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol.  580 
  
Supplementary Material
Click here to download Supplementary Material: 2018_07_09_Lpa and CVD risk_supplement_clean.docx
  
Supplementary Material
Click here to download Supplementary Material: 2018_07_09_Lpa and CVD risk_supplement_tracked.docx
